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Abstract
NK cell transplantation has been increasingly used to treat cancers that are resistant to chemotherapy.
However, not all cancers are susceptible to NK cell killing. The prevalence and mechanisms of NK cell
resistance have not been well elucidated. Because NKG2D is a major activating receptor on NK cells, we
sought to test the hypothesis that NKG2D is the primary pathway in tumor cell recognition. Herein, we
comprehensively assessed 20 cancer cell lines representing a broad array of cancer types. In line with our
primary hypothesis, no cancer cell lines that expressed low levels of NKG2D ligands were susceptible to
NK cell lysis. Furthermore, we found that only 30% of the cancer cell lines were susceptible to NK cell
killing and all of them expressed high level of NKG2D ligands. The dependency on NKG2D pathway in
these NK susceptible cells was confirmed by anti-NKG2D antibody blocking experiments. For the 70% of
cell lines that were resistant to NK cells, 65% were due to silencing of NKG2D ligand expression, whereas
35% were due to insufficient NKG2D activation. For the former cell lines, NKG2D ligand expression was
found to be downregulated at the mRNA or protein level. By histone acetylation or proteasome
modulation, these regulatory checkpoints could be circumvented to obtain sufficient surface expression
of NKG2D ligands to overcome NK resistance. For the latter cancer cell lines that were NK resistant
despite high NKG2D ligand expression, KIR inhibition was found to override NKG2D activation in 80% of
these cancers. MHC blockade successfully increased NK susceptibility of these cell lines. In the
remaining 20%, downregulation of ICAM-1 was responsible for NK resistance. In conclusion, we
successfully obtained sufficient evidence to support our hypothesis that NKG2D is the primary pathway
for tumor cell recognition. Evasion of the NKG2D pathway is common through NKG2D ligand silencing,
KIR inhibition, or inadequate expression of adhesion molecules to mediate immune-synapse formation.
Because these resistance mechanisms are readily amenable to therapeutic alteration, NK cell
transplantation holds promise for future cancer therapy.
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ABSTRACT
NK cell transplantation has been increasingly used to treat cancers that are
resistant to chemotherapy. However, not all cancers are susceptible to NK cell killing.
The prevalence and mechanisms of NK cell resistance have not been well elucidated.
Because NKG2D is a major activating receptor on NK cells, we sought to test the
hypothesis that NKG2D is the primary pathway in tumor cell recognition. Herein, we
comprehensively assessed 20 cancer cell lines representing a broad array of cancer types.
In line with our primary hypothesis, no cancer cell lines that expressed low levels of
NKG2D ligands were susceptible to NK cell lysis. Furthermore, we found that only 30%
of the cancer cell lines were susceptible to NK cell killing and all of them expressed high
level of NKG2D ligands. The dependency on NKG2D pathway in these NK susceptible
cells was confirmed by anti-NKG2D antibody blocking experiments. For the 70% of cell
lines that were resistant to NK cells, 65% were due to silencing of NKG2D ligand
expression, whereas 35% were due to insufficient NKG2D activation. For the former cell
lines, NKG2D ligand expression was found to be downregulated at the mRNA or protein
level. By histone acetylation or proteasome modulation, these regulatory checkpoints
could be circumvented to obtain sufficient surface expression of NKG2D ligands to
overcome NK resistance. For the latter cancer cell lines that were NK resistant despite
high NKG2D ligand expression, KIR inhibition was found to override NKG2D activation
in 80% of these cancers. MHC blockade successfully increased NK susceptibility of these
cell lines. In the remaining 20%, downregulation of ICAM-1 was responsible for NK
resistance. In conclusion, we successfully obtained sufficient evidence to support our
hypothesis that NKG2D is the primary pathway for tumor cell recognition. Evasion of the
NKG2D pathway is common through NKG2D ligand silencing, KIR inhibition, or
inadequate expression of adhesion molecules to mediate immune-synapse formation.
Because these resistance mechanisms are readily amenable to therapeutic alteration, NK
cell transplantation holds promise for future cancer therapy.
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CHAPTER 1.

INTRODUCTION

Immunobiology of NK Cells
The first documented description of natural killer (NK) cells dates back to 1975
when Rolf Kiessling described a unique subset of large granular lymphocytes that can
directly lyse tumor cells without prior sensitization. Kiessling isolated and characterized
these cells and named them natural killer due to their ‘natural’ occurrence and ability to
kill tumor cells [1, 2]. In humans, NK cells are the third largest lymphocyte population
comprising of 5-10% of peripheral blood lymphocytes. They are derived from CD34+
hematopoietic progenitor cells [3] in the bone marrow and are relatively short lived
(approximately 2 weeks) [4]. NK cells are phenotypically characterized by the surface
expression CD56 and the absence of CD3 (CD56+ CD3-) [5]. Furthermore, human NK
cells can be divided into two functional subsets based on their surface expression of
CD56: CD56bright immunoregulatory cells and CD56dim cytotoxic cells [6]. Around 90%
of peripheral blood and spleen NK cells are CD56dim and express perforin. These cells are
cytotoxic through granzyme degranulation. In contrast, CD56bright cells lack perforin and
are predominant in the lymph nodes and tonsils. These cells readily produce IFN-γ in
response to stimulation with interleukin (IL)-12, 15 and 18 [7, 8].
Effector functions of NK cells
Cytotoxicity
Natural cytotoxicity of NK cells is mediated via perforin/granzyme pathway or
the death receptor pathway. Perforin/granzyme-mediated apoptosis is the principal
pathway used by NK cells to eliminate virus-infected or tumor transformed target cells
[9]. Studies in perforin-deficient mice have revealed that this protein is required for most
NK cell cytotoxicity [10]. After effector–tumor-cell interaction (conjugation), cytotoxic
granules become re-oriented towards the tumor cell, and their contents are secreted into
the intercellular cleft between effector and tumor cells in a calcium-dependent manner.
These granules contain perforin, which disturbs the tumor-cell membrane and allows the
entry of serine proteases known as granzymes [9]. The two most-abundant granzymes, A
and B, have been implicated in mediating apoptosis of target cells through caspasedependent and -independent pathways [11]. Furthermore, NK cells can also induce
apoptosis of their targets via death receptor pathways [12]. Some NK cells express FAS
ligand (FASL) or tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL).
These bind to and activate their receptors, FAS and TRAIL receptor (TRAILR),
respectively, which are expressed by some tumor cells inducing tumor cell apoptosis [13,
14].
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Cytokine production
NK cells are major producers of IFN-γ in physiological and pathological
conditions [15]. They also produce both proinflammatory and immunosuppressive
cytokines such as tumor necrosis factor-α (TNF-α) and IL-10 respectively. By production
of cytokines, NK cells can act as regulatory cells to influence various cell types such as T
cells, B cells and dendritic cells (DCs). NK cell derived IFN-γ and TNF-α helps NK cells
cross talk with DCs in many ways including NK cell killing of immature DC and the
promotion of DC maturation which leads to enhanced antigen presentation to T cells [16].
Production of IFN-γ by NK cells helps shape T cell responses in lymph nodes, possibly
by a direct interaction between naive T cells and NK cells migrating to secondary
lymphoid compartments from inflamed peripheral tissues [17, 18]. Furthermore, NK cells
also secrete many chemokines that is key to their colocalisation with other hematopoietic
cells such as DCs in areas of inflammation [19].
Regulation of effector functions
NK cells can distinguish between healthy cells and abnormal cells by using a
sophisticated repertoire of cell surface receptors that control their activation, proliferation
and effector functions. The activating receptors stimulate NK cell activity while the
inhibitory receptors dampen NK cell responses. Regulation of NK cell function was
initially explained by the “missing-self” hypothesis proposed by Karre et al. Their
seminal study in 1986 noted that NK cells appear to be actively inhibited from
responding when they encounter certain tumor cells that express MHC class I [20].
Because MHC class I molecules are expressed by all nucleated cells, they are an ideal
universal marker of healthy self. The ability of NK cells to lyse cells ‘missing-self’
predicted the existence of inhibitory receptors and revealed a mechanism whereby NK
cells provided immune surveillance for cells that had downregulated MHC class I, a
frequent event in cellular transformation or virus infection to avoid recognition by CD8+
T cells [21, 22] (Figure 1-1). However, missing from the ‘missing-self’ hypothesis was
any molecular basis of how NK cells are activated when they encounter tumor or virus
infected cells or how NK cells efficiently lyse target cells that have an intact MHC class I
surface expression.
Discovery of activating receptors on NK cells, led to the ‘dynamic equilibrium’ or
‘rheostat’ concept- a contemporary modification of the ‘missing-self’ hypothesis [23]
(Figure 1-2). According to this concept, NK cells sense the density of various surface
molecules expressed on the target cells [24]. The integration of these distinct signals
dictates the quality and the intensity of the NK cell response. In essence, inhibitory
receptors serve as a rheostat, regulating and dampening activating signals, rather than
completely terminating them. When NK cells and target cells interact, the information is
interpreted by an analog and not a binary process. Thus, when an NK cell encounters a
target cell with no inhibitory or activating ligand, there is no target cell lysis by the NK
cell (Figure 1-2A). If the target cell expresses the inhibitory MHC class I but no
activating ligands, NK cells do not lyse the target cells due to the existence of
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A

B

Figure 1-1. Regulation of NK cell function according to the 'missing-self'
hypothesis.
(A) Normal cells expressing self MHC class I molecules engage inhibitory receptors on
NK cells. Recognition of self MHC class I spares normal cells from NK lysis. (B) If the
target cell loses expression of MHC class I molecules, owing to viral infection or
transformation, then the MHC-binding inhibitory receptor at the surface of the NK cell is
not engaged. Thus, the NK cell does not receive inhibitory signals and therefore lyses the
target cell. In this case, the target cell is perceived by the NK cell to be ‘missing self’.
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A

B

C

D

Figure 1-2. Regulation of NK cell function as explained by the dynamic
equilibrium concept.
Depiction of possible outcomes of encounters between NK cells and target cells.
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inhibitory signals (Figure 1-2B). When the target cells express activating but no
inhibitory ligands, NK cells lyse the target cells (Figure 1-2C). However, in the presence
of both activating and inhibitory signals, the outcome is determined by summation of
strength of the signals (Figure 1-2D). The amount of activating and inhibitory receptors
on the NK cells, the amount of ligands on the target cells as well as the qualitative
differences in the signals transduced determine the extent of NK response. The failure of
NK cells to lyse target cells can be either due to active inhibition or alternatively due to
the absence of sufficient activation. In experimental models, when multiple activating
receptors are engaged simultaneously [25] or when a sufficiently potent NK activating
receptor is stimulated [26, 27], NK cells are capable of lysing target cells even in the
presence of inhibitory signaling through ligation of inhibitory receptors and MHC class I
molecules. In summary, the dynamic regulation of NK cell effector functions proposes
that the balance of signals from inhibitory and activating receptors together dictate the
fate of the target (Figure 1-3).
Lysis of target cells by NK cells involves 3 sequential steps, each of which are
under tight regulation. First, NK cells adhere to target cells resulting in the formation of
immune-synapse. This is followed by NK cell activation by integration of signals from
the activating and inhibitory receptors and finally granule exocytosis resulting in target
cell death (Figure 1-4). The NK cell detection system includes a variety of cell surface
adhesion receptors, activating receptors and inhibitory receptors, the engagement of
which regulates NK cell activities. Conjugate formation between NK effectors and target
cells is a prerequisite for cytotoxicity, and is primarily mediated by binding of the NK
surface adhesion molecules LFA-1 (CD1la/CDl8) and CD2 to their respective target cell
ligands, intracellular adhesion molecule-1 (CD54) and LFA-3 (CD58) [28]. In humans,
the MHC class I specific inhibitory receptors include the killer cell immunoglobulin-like
receptors (KIRs) and the lectin–like CD94-NKG2A heterodimers [29]. These inhibitory
receptors carry in their cytoplasmic tails immunoreceptor tyrosine based inhibition motifs
(ITIMs), which become phosphorylated upon receptor engagement and recruit tyrosine
phosphatases SHP-1 and SHP-2. These tyrosine phosphatases suppress NK cell responses
by dephosphorylating protein substrates of the tyrosine kinases linked to the activating
NK cell receptors. Activating receptors on human NK cells include the FcγRIIIA (CD16)
receptor involved in antibody-dependent cell cytotoxicity (ADCC) [30], the natural
cytotoxicity receptors (NCRs) including NKp46 [31], NKp44 [32], NKp30 [33] and the C
type lectin-like superfamily member NKG2D [34]. Some of these activating receptors
contain immunoreceptor tyrosine based activation motifs (ITAMs) in their cytoplasmic
domains and some mediate signals through adaptor proteins like DNAX activating
protein of 10kDa (DAP10). In addition, NK cells also express co-receptors that cannot
directly mediate lysis of target cells but play an important role in reinforcing the strength
of activating signals [35]. These include the receptors 2B4 [36], NTB-A [37], DNAM-1
[38] and NKp80 [39].
Both ITAM-dependent signaling and DAP10-dependent signaling of NK
activating receptors converge on a common NK cell cytotoxicity pathway. This common
pathway involves the activation of Rac, which sequentially leads to activation of the
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Figure 1-3. Outcome of NK cell response is dependent on the balance between
activating and inhibitory signals.
According to the ‘dynamic equilibrium’ concept, the balance of activating and inhibitory
signals ultimately decides the fate of the target cell.
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Figure 1-4. Sequential steps involved in the NK lysis of target cells.
Three steps involved in the lysis of target cells by NK cells. 1) Adhesion mediated by the
adhesion receptors and ligands results in the formation of immunosynapse. 2)
Engagement of activation and inhibitory receptors with their respective ligands,
integration of signals and NK cell activation. 3) The activated NK cell undergoes granule
exocytosis resulting in target cell death.
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mitogen activated protein kinase (MAPK), extracellular signal regulated kinase (ERK)
and mitogen activated or extracellular signal regulated protein kinase kinase (MEK) [40]
resulting in the redistribution of intracytoplasmic granules and their release. Thus
signaling by co-receptors like DNAM-1 (ITAM-dependent) can provide a synergistic
signal to NKG2D signaling which is mediated through DAP10.
Inhibition by ITIM bearing inhibitory receptors of activating signaling is saturable
and proportional to the magnitude of engagement of both types of receptors by their
cognate ligands. When ITIM bearing receptors engage their ligands, the tyrosine residue
is phosphorylated, probably by a Src family kinase, resulting in the recruitment of the
lipid phosphatase SHIP-1or the tyrosine phosphatases SHP-1 or SHP-2 [41]. The
inhibitory NK receptors recruit these phosphatases to the interface between the NK cell
and its prospective target cell, and these tyrosine phosphatases suppress NK cell
responses by dephosphorylating the protein substrates of the tyrosine kinases linked to
activating NK receptors.
Inhibitory and activating receptors act in concert and co-aggregation between
activating and inhibitory receptors is required for inhibition to occur [42]. A dynamic
equilibrium is set between the “strength” of activating and inhibitory signals and is
relayed by the level of tyrosine phosphorylation of critical signaling components (like
Vav1) that can serve as targets for both Syk-family protein tyrosine kinase and SHP-1 or
SHP-2 protein phosphatases [43].
In our study, we focused on the NKG2D pathway because unlike NCRs that are
expressed at different surface densities in different NK cells, the expression of NKG2D is
relatively homogeneous [44]. Both NCR bright and NCR dull NK clones show comparable
surface densities of NKG2D [45, 46]. Also till date, tumor ligands for the NCRs remain
undefined except for B7-H6 which has been recently identified as a ligand for NKp30
[47].
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The NKG2D Pathway
Natural Killer Group 2 member D (NKG2D) was identified in a screen for genes
that are preferentially expressed by human NK cells [48, 49]. Interest in NKG2D was
prompted by a curiosity in identifying activating receptors used by NK cells to recognize
target cells. In humans, NKG2D is expressed on NK cells, CD8+ T cells and γδ T cells
[34, 50, 51]. NKG2D is encoded by a gene on human chromosome 12 mapping within
the natural killer (NK) gene complex. This receptor belongs to the type II C-type lectin
like family of transmembrane proteins [52]. In humans, NKG2D is expressed as a
homodimer in association with its adaptor molecule DNAX activating protein of 10kDa
(DAP10) [53] (Figure 1-5). Each NKG2D homodimer assembles on the cell surface with
two dimers of DAP10, thereby forming a hexameric structure, which reduces the
threshold of ligand levels required for inducing signal transduction [54]. The association
of NKG2D with DAP10 is necessary for signaling and considered important for its cell
surface expression. DAP10 is a type I transmembrane protein with conserved aspartic
acid residues in its transmembrane region that interacts with a positively charged arginine
residue in the transmembrane region of NKG2D [55]. Engagement of NKG2D in human
NK cells results in tyrosine phosphorylation of DAP10 and coupling of the receptor to the
phosphatidylinositol-3-kinase (PI3K)/ growth factor receptor bound protein 2 (Grb2)-Vav
pathway [56]. The PI3K pathway plays a critical role in regulating NK cytotoxicity by
promoting perforin and granzyme B movement toward target cells and DAP10-mediated
cytokine production [40, 57].
NKG2D ligands are diverse proteins that are structurally similar to MHC class I
molecules (Figure 1-5). In humans, NKG2D ligands fall into two families- the MHC
class I chain related gene A (MICA) and B (MICB) family and the cytomegalovirus UL16 binding protein (ULBP) family comprising of ULBP1-ULBP3 proteins. First evidence
of a protein that binds to NKG2D came from studies showing that a soluble form of
MICA binds to various lymphocyte subsets. A monoclonal antibody blocking the
interaction was subsequently shown to bind NKG2D [34]. Further analysis showed that
MICB- a close relative of MICA (84% identical) also binds NKG2D [58]. No functional
homologues of MICA and MICB are present in mice. MICs are highly glycosylated
transmembrane proteins possessing the characteristic MHC class I like α1, α2 and α3
domains [59, 60]. Despite the presence of the α3 domains, MICA and MICB do not
associate with β2 microglobulin or require β2 microglobulin for their surface expression.
MICs are highly polymorphic with more than 50 MICA and 13 MICB alleles so far
reported [61].
A distinct approach identified three related human proteins that bind to the UL16
protein of human cytomegalovirus (HCMV). UL16 was studied because it was a
candidate virus protein involved in immune escape. ULBP1 was first identified on the
basis of its binding to the HCMV glycoprotein UL16. Subsequent database searches for
homologues of ULBP1 led to the identification of additional ULBP members. ULBPs
also contain α1 and α2 domains but lack the α3 domain and are expressed as
glycosylphosphatidylinositol (GPI) anchored proteins [62, 63]. Notably, the MICs and
ULBPs only share 20-25% sequence homology [64].
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Figure 1-5. NKG2D receptor and ligands in humans.
Illustration of the human NKG2D receptor and its ligands. Also depicted is the classical
MHC class I molecules.
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Given that the NKG2D ligands vary in structure and sequence, it is pertinent to
wonder whether all ligands are equally able to bind to NKG2D and invoke an activating
signal in immune cells. The binding of NKG2D to its various ligands is generally of high
affinity than many immunoreceptor ligand interactions [65]. Three dimensional structure
analyses indicate that ligand binding to NKG2D is focused on key tyrosine residues that
are rigidly held in the NKG2D structure. Crystal structure studies of human NKG2D in
complex with MICA and ULBP3 reveal that NKG2D binds to the α1/α2 helices of the
ligands. Notably, most of the receptor amino acid residues that dominate binding to
different ligands are the same and several of the contact residues between different
ligands are conserved, especially those that contribute most of the binding energy.
Therefore, despite differences in the amino acid sequences of different NKG2D ligands,
they interact with the receptor similarly, and the receptor does not seem to undergo
marked conformational changes (induced fit) to accommodate different ligands. Rather
binding of NKG2D with diverse ligands is explained as ‘rigid adaptation’, in which a
rigid binding site on NKG2D makes diverse interactions with a series of structurally
distinct ligand surfaces by utilizing a core set of residues capable of multifarious bonds
[66]. Binding studies of human NKG2D with MICA reveal that each NKG2D
homodimer can only bind with a single monomeric ligand suggesting that NKG2D can
bind to only one ligand at a time. [67, 68].
The NKG2D ligands are encoded by genes in the hosts’ own genome i.e. they are
self proteins as opposed to foreign antigens. Moreover, they are either absent or present at
low levels on normal healthy cells but their expression is often upregulated in
pathological conditions like infection or tumor transformation. Therefore recognition of
NKG2D ligands by NKG2D is referred to as ‘induced-self’ recognition. Although
NKG2D ligands are often upregulated as a result of cellular stress, infection or
tumorigenesis, the mechanisms that regulate their expression are still ill-defined. Several
studies indicate that the regulation of individual NKG2D ligands differs substantially in
particular tumors or infected cells, suggesting that the diverse NKG2D ligands do not
simply reflect the redundant expression of molecules with the same function.
The first insight into the regulation of NKG2D ligands came from analysis of the
promoters of MICA and MICB, which were found to resemble the promoter of heat
shock protein (HSP)70 [69]. Accordingly, expression of MICA is induced by heat shock
[59]. On the basis of sequence analysis, investigators have shown that heat shock
elements may also exist in some ULBP genes but it hasn’t been demonstrated that these
genes are regulated by heat shock [70]. It has also been proposed that NF-κB may
stimulate MICA transcription and an NF-κB binding site in intron 1 of the MICA gene
has been described [71, 72]. Studies of MICA, MICB and ULBP1 genes have identified
potential binding sites for Sp family transcription factors [69, 73]. In addition, the DNA
damage pathway has also been implicated in induction of NKG2D ligands [74, 75]. DNA
damaging agents activate ATM and ATR thereby activating the DNA damage response
resulting in ligand induction. Thus, DNA damage response, which arrests the cell cycle
and enhances DNA repair functions, or triggers apoptosis, also alerts the immune system
in response to potentially dangerous cells through the activation of NKG2D. However,
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the mechanism of regulation of NKG2D ligands by the DNA damage response still
remains poorly understood [76].
There are also some reports of micro RNA mediated regulation of NKG2D ligand
expression. Initially, HCMV and other virus encoded micro RNA’s were shown to
downregulate expression of MICA, MICB or ULBP3 [77-79]. However, subsequently
Stern-Ginossar et al showed that certain cellular micro RNA’s can also target the MIC
transcripts. They reported that cellular micro RNAs maintain threshold levels of MICA
and MICB in normal cells while transcriptional induction of the ligand genes can
overcome this buffering capacity of micro RNAs [80]. Some studies on post translational
regulation of NKG2D ligands have also been reported but primarily in the mouse system.
Nice et al reported that the mouse NKG2D ligand MULT1 is polyubiquitinated and
degraded in unstressed cells while in cells subjected to heat shock or UV irradiation
MULT1 was less ubiquitinated and expressed on the cell surface [81, 82]. Although there
is no direct evidence yet of such regulation of human NKG2D ligands, the intracellular
sequestration of MICA in melanoma cells may perhaps be due to a similar or related
mechanism [83]. Post translational regulation of MICs has been reported in the context of
viral infections. Kaposi’s sarcoma-associated herpesvirus (KSHV) encoded E3 ubiquitin
ligase K5 can downregulate cell surface MICA and MICB. However, unlike MULT1,
ubiquitination of MICA resulted in redistribution of MICA from the plasma membrane
but not its degradation [84].
One of the most important findings in NKG2D ligand regulation is that ligands
are proteolytically cleaved from the cell surface or excreted in exosomes. Soluble forms
of MICs and ULBPs have been observed in cancer patients and cancer cell culture
supernatants [85-90]. The presence of soluble ligands may act as indicators of poor
prognosis in cancer patients [91]. Shedding of ligands was shown to be due to cleavage of
extracellular domain of NKG2D ligands by matrix metalloproteinases (MMPs) [86, 89].
Also, the membrane associated disulphide isomerase endoplasmic reticulum protein 5
(ERP5) was shown to be responsible for proteolytic shedding of MICA [92]. In one
study, ULBP3 in tumor cell culture supernatants was associated with exosomes while
ULBP2 was primarily in the cleaved form [93]. Shedding of NKG2D ligands can result
in lowered NK susceptibility of tumor cells due to lower surface expression of the ligands
[90]. Although, some studies also report downmodulation of the NKG2D receptor in the
presence of soluble ligands [85, 93], some others propose contrasting observations [89,
94, 95]. Taken together, although there is some understanding of how NKG2D ligands
are regulated, a lot is still unknown. Increased knowledge of the differential expression
and regulation of NKG2D ligands will contribute to our understanding of tumor
immunosurveillance and help in therapeutic interventions that induce NKG2D mediated
immune responses.
The NKG2D system has evolved to function as a sensory system to alert the
immune system in response to infections and tumors. Initially, Bauer et al reported that
target cells ectopically expressing NKG2D ligands are efficiently eliminated by NKG2D
expressing immune cells [34, 96, 97]. These observations were subsequently made in
vivo as well [26, 27]. A noteworthy observation of NKG2D in tumor immunity was
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provided by NKG2D neutralization experimental models. When mice were injected with
antibody to neutralize NKG2D, they showed an increased susceptibility to carcinogen
methylcholanthrene (MCA) induced fibrosarcoma in comparison to the isotype control
treated mice [98]. Furthermore, a critical role of NKG2D in tumor immunosurveillance in
vivo was proposed by Guerra et al. They reported that NKG2D deficient mice when
crossed to TRAMP mice that spontaneously develop prostrate adenocarcinoma showed a
higher incidence of aggressively arising tumors in comparison to the control mice [99]. In
addition to tumor surveillance, NKG2D has also been implicated in pathogen immunity
[62].
The interesting promiscuous nature of NKG2D also deserves a mention. Most NK
receptors bind to one or two proteins but NKG2D is a notable exception to this rule.
Although the exact reason for ligand diversity for a conserved receptor isn’t known, there
are several speculative theories. One of the notions is that selection pressure by viruses
has led to the diversity in NKG2D ligands. Infection of cells by viruses particularly
HCMV, Influenza A and Epstein Barr virus has shown to induce NKG2D ligand
expression [100-102]. However, HCMV deploy immunoevasins that prevent the surface
expression of NKG2D ligands and help escape NK killing. Interestingly however, each
immunoevasin only has limited capacity to bind NKG2D ligands. For example, the
HCMV protein UL16 can intracellularly sequester MICB, ULBP1 and ULBP2 but not
MICA and ULBP3 [103-105]. In this scenario, having multiple NKG2D ligands is
therefore beneficial to the host to alert its immune system to viral infection. Competition
with viruses, thus presents an attractive theory for the presence of NKG2D ligand
diversity. Another theory is the differential binding affinities of various ligands to
NKG2D. Theoretically, the expression of a lower affinity ligand would not invoke a
powerful immune response and vice versa. However, these differences have not yet been
shown to have a functional impact on NK responses [106]. Having so many ligands with
varying binding affinities would allow for greater flexibility in the decision of the
effector NK cells to activate or not, depending on the activation threshold set by signals
from the engagement of other receptors. A third theory is that malignant transformation is
a drive for NKG2D ligand diversity. From our observations and others, expression of
different NKG2D ligands was seen to be under the control of different cancer related
stress response pathways [107-109]. Possessing multiple NKG2D ligands that are
regulated differently would thus provide the host with a relatively fail-safe mechanism
for alerting the immune system.
Clinical Significance of NK Cells
Surgery, chemotherapy and ionizing radiation have been used for decades as
primary treatment strategies to eliminate tumors in patients. However, the development
of resistance to drugs or radiation has led to significant tumor relapse. Hence the past few
decades have focused on therapies that harness the power of the immune system. Tumor
immunotherapy using various therapeutic agents including cytokines, monoclonal
antibodies, vaccines, adoptive cell transfers has become an attractive tool for the
treatment of malignancies [110, 111]. Cellular therapy with NK cells is increasingly
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gaining importance and till date a number of clinical trials have tapped the beneficial
anti-cancer potential of NK cells.
Evidence of the anti-cancer effects of NK cells came from an 11 year follow up
study that showed that patients with low NK cell cytotoxicity were associated with a
greater risk of cancer [112]. Various other groups reported that high levels of tumor
infiltrating NK cells are associated with favorable tumor outcome in cancer patients
[113]. The greatest revelation of NK cells in tumor control was shown in the context of
allogeneic hematopoietic stem cell transplantation (HSCT). In 2002, Ruggeri et al
demonstrated a significant long term benefit and prevention of leukemia relapse for
haploidentical mismatched transplant recipients suffering from acute myeloid leukemia (
AML) [114]. T cell depleted donor grafts containing alloreactive NK cells improved the
overall survival of patients in remission by mediating an enhanced graft versus leukemia
(GVL) effect and significantly reducing graft versus host disease (GVHD). The decrease
in GVHD was explained by donor NK cell alloreactivity against host antigen presenting
cells (dendritic cells) that prevents presentation of host antigens to donor graft T cells
[115, 116]. In addition, non-transformed tissues generally do not express ligands for NK
activating receptors, hence alloreactive NK cells do not cause GVHD [117].
Outside the context of allogeneic HSCT, infusion of allogeneic NK cells has also
been explored as a means of cancer therapy. Several protocols of clinical grade NK cells
purification and expansion are now validated and studies have shown that the infusion of
NK cells is safe in humans [118-124]. However, no firm conclusions can be made
regarding the clinical benefits of these NK cell infusions as the clinical efficacy of these
NK therapies has been modest [125]. Nevertheless available data indicate that NK
infusions are safe and can generate anti-tumor responses and long term remission in some
patients. NK cells also express CD16 on their surface which enables them to recognize
antibody coated target cells and trigger NK mediated ADCC. Strong evidence supporting
role for NK mediated ADCC comes from anti-CD20 (Rituximab) treated non-Hodgkin’s
lymphoma patients and anti-HER2 (Trastuzumab/Herceptin) treated metastatic breast
cancer and gastric carcinoma patients [126-129]. Additionally, potential use of NK cell
lines as a source of therapeutic allogeneic NK cells has also been reported. NK92 cells
have been demonstrated to be safe and with potentially beneficial anti-tumor effects. It
has received FDA approval for testing in patients with advanced malignant melanoma
and renal cell carcinoma and is currently the only NK cell line that has entered clinical
trials [130-133].
In addition, genetically modified NK cells expressing chimeric antigen receptors
(CARs) has also been reported by various groups. Successful expression of CARs against
CEA, CD33, CD20, and Her2/neu has been shown in the context of NK cell lines where
they improved NK responses in vitro and in vivo [134-137]. Similar observations have
been reported with primary NK cells as well [138, 139]. Imai et al successfully
demonstrated that NK cells from B-ALL patients genetically modified to express CD19CAR efficiently killed autologous leukemic cells [140].
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A proliferation of studies is currently exploiting the immunotherapeutic potential
of NK cells for cancer treatment. Although the results of these NK based
immunotherapeutic strategies to date are promising in experimental systems, their clinical
efficacy in humans has been modest, presumably due to tumor escape mechanisms. With
a greater understanding of NK cell recognition of target cells, treatment strategies are
now being focused on modulation of NK cell receptors systems. NKG2D, being a major
activating receptor on NK cells has been studied in the clinical setting as well. The
importance of NKG2D has come from correlative observations of impaired NKG2D
function with disease stages in cancer patients. For example, Wu et al reported that
defective NKG2D mediated NK function correlated with cancer stages in prostate cancer
patients [141]. Similar observations were made in multiple myeloma, colon cancer and
glioma patients as well [88, 142, 143]. In a clinical trial involving vaccination with
irradiated, granulocyte-macrophage colony stimulating factor (GM-CSF)-secreting tumor
cells and antibody blockade of cytotoxic T lymphocyte-associated antigen 4 (anti CTLA4) for melanoma therapy, patients who generated anti-MICA antibodies during the
therapy showed significantly better clinical outcomes than those who did not [144]. The
beneficial effect was shown to act through antibody antagonizing soluble MICA induced
suppression of NK and CD8 T cell responses.
In addition, a new and interesting mechanism to utilize the NKG2D mediated
immunity in tumor therapy has been reported. This strategy involves expression of
NKG2D-CAR on T cells or NK cells for adoptive cell therapy. The chimeric NKG2D is
not downregulated by soluble NKG2D ligands and can also overcome inhibitory
signaling. This approach has been demonstrated to be very effective in various
experimental models [145-149]. NKG2D-CAR engineered T cells are currently in phase I
clinical trials for the treatment of ovarian cancer patients. Recently, Chang et al reported
the expression of NKG2D-CAR on activated NK cells and demonstrated their anti-cancer
potential in vitro and in vivo [150]. A few therapies utilizing bispecific protein to target
NKG2D or NKG2D ligands have also shown therapeutic potential. A ULBP2-BB4
bispecific protein increased susceptibility of multiple myeloma cell lines to NK mediated
cytotoxicity and enhanced the elimination of a xenograft tumor when combined with
adoptive transfer of PBMCs [151]. It was shown that ULBP2 engaged the NKG2D
receptor while BB4 bound CD138, which is overexpressed on multiple myeloma cells.
Collectively, NK cells as tools for immunotherapy in cancer have shown promise
in the clinic. However, the clinical efficacy of these NK based therapies can be further
augmented by modulating receptor pathways such as NKG2D. The ability to manipulate
not only the balance of activating and inhibitory receptors on NK cells but also their
cognate ligands and the NK sensitivity of tumor cells, opens new perspectives in NK cell
based immunotherapy. Thus, further benchside research focused on understanding
mechanisms of NKG2D mediated NK resistance is needed to get a clearer picture of the
clinical significance of this pathway that can eventually help in designing more effective
NK therapies.
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CHAPTER 2.

HYPOTHESES AND AIMS

Problem at Hand
NK transplantation is being increasingly used for the treatment of chemorefractory cancers. Although various clinical trials have evaluated the safety and efficacy
of NK based cancer therapies, the results were conflicting. While the safety of NK
therapies has been firmly established, the clinical effectiveness has been modest. One of
the reasons for the inconsistent clinical usefulness of NK therapies might be variable NK
evasion strategies employed by tumor cells. The success of NK therapies relies heavily
on the NK susceptibility of cancer cells. However, till date the prevalence and
mechanisms of NK resistance has not been well elucidated. Therefore a better
understanding of the predominance and mechanisms of NK resistance is needed for
designing more effective NK therapies in the future.
Central Hypothesis
NKG2D is a major activating receptor on NK cells. Hence, in our study we
focused on this receptor pathway and examined the NK resistance mechanisms employed
by tumor cells. We hypothesized that NKG2D is the primary pathway for tumor cell
recognition; thereby, susceptible tumors activate NK cell through NKG2D, whereas
resistant tumors evade NKG2D recognition.
Specific Aims
Aim 1- To determine the prevalence of NK cell susceptibility in cancer and the
role of NKG2D. NK susceptibility was evaluated in a spectrum of cancer cell lines and
the role of NKG2D in cancer was investigated by determining the surface expression of
NKG2D ligands and their contribution to NK susceptibility. Furthermore, correlation
studies were undertaken to test the hypothesis that NK susceptibility directly correlated
with the level of NKG2D ligands expressed by tumor cells.
Aim 2- To identify the molecular mechanisms of NK resistance, if any. The two
hypothetical mechanisms included a) the absence of NKG2D activation, or b) the
presence of NKG2D activation but overridden by inhibitory signals.
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CHAPTER 3.

MATERIALS AND METHODS
Cancer Cell Lines

K562, U937, SEM, RS4;11, RPMI 6666, Hs 445, Daudi, HCT116, HeLa, CAL
27, RD and 293T cells were obtained from American Type Culture Collection (ATCC).
Jurkat, MOLT-4, HDLM-2, L-428, L-540, L-591 and MV4-11 were purchased from the
German Resource Center for Biological Material (DSMZ, Braunschweig, Germany). The
cell lines NB-1691 (from Dr. Peter Houghton, Center for Childhood Cancer, Nationwide
Children's Hospital Columbus, OH) and CHLA-255 (from Dr. C. Patrick Reynolds,
Children’s Hospital of Los Angeles, Los Angeles, CA) were established from patients
with different metastatic sites, stages and N-myc amplification. NKL cell line was a kind
gift from Dr. Francisco Borrego, NIAID/NIH, Rockville, MD. YT-Indy cell line was a
generous gift from Dr. Zacharie Brahmi, Indiana University, Indianapolis, IN. All cell
lines were cultured as recommended and passaged with no more than 3 months. Routine
authentication was conducted by typical morphology observation.
Cell Purification
Peripheral blood mononuclear cells (PBMC) were collected from healthy donors
and from pediatric leukemia patients with approval from Institutional Review Board and
written informed consent from donors, patients, or legal guardians. Briefly, the specimens
were layered over Ficoll-Hypaque gradient (GE Healthcare, Piscataway, NJ) and
centrifuged at 2,300 rpm for 20 minutes. The light-density fraction was collected,
washed, and used immediately. NK cells were enriched from healthy donor PBMCs using
an NK Cell Isolation Kit (Miltenyi, Germany) according to the manufacturer’s
instructions. The purity of the NK cells was more than 95% in all experiments as
determined by flow cytometry. Enriched NK cells were activated overnight with 10U/mL
of recombinant interleukin-2 (R&D Systems, Minneapolis, MN) in all experiments unless
indicated otherwise.
Phenotypic Analysis by Flow Cytometry
The following antibodies (from commercial suppliers) were used for phenotypic
analysis: phycoerythrin (PE)-conjugated anti-MICA (159227) and anti-ULBP2 (165903);
fluorescein isothiocyanate (FITC)-conjugated anti-ULBP1 (170818) and anti-ICAM-1
(84H10); allophycocyanin (APC)-conjugated anti-CD56 [N901(NKH-1)] and anti-MICB
(236511); Alexa fluor 488-conjugated anti-PI-9 (7D8); phycoeryhtrin-Texas redconjugated anti-CD3 (UCHT1) and unconjugated anti-ULBP3 (166510). Intracellular
staining was performed using the Cytofix/Cytoperm kit (BD Biosciences, San Jose, CA)
according to the manufacturer’s protocol. Flow cytometry analyses were conducted with
LSRII or Accuri C6 flow cytometers (both from BD Biosciences) and the data were
analyzed with FlowJo V10 (Tree Star, Ashland, OR).
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Retroviral Constructs and Transduction of Cells
Full length MICA*001 was amplified by PCR from HCT116 cell line and cloned
into pMSCV-IRES-GFP retroviral vector (obtained from vector lab at St.Jude). Retroviral
supernatants were generated by co-transfecting 293T cells with plasmids encoding VSV
gag/pol and env and pMSCV retroviral constructs using Lipofectamine 2000 (Invitrogen,
Grand Island, NY) according to the manufacturer’s protocol. After 48 hours of
transfection, viral supernatant was harvested and used for transducing RS4;11, Daudi and
NB-1691 cell lines by spinoculation. Virus supernatants were mixed with cell pellets and
centrifuged at 3900 rpm for 90 mins at 32°C in the presence of 8 ug/mL polybrene
(Sigma, St.Louis, MO). Stable cell lines were established by sorting for GFP and MICA
double positive cells by flow cytometry.
NK Cytotoxicity Assay by BATDA
Target cells, including those from cell lines and primary patient samples, were
labeled with DELFIA BATDA reagent (PerkinElmer Life and Analytical Sciences,
Waltham, MA) according to the manufacturer’s instructions. After labeling, the cells
were washed and then co-cultured with effector cells at 20:1 ratio (effector to target) for 2
hours at 37°C. Cell supernatants were then mixed with DELFIA Europium solution, and
the fluorescence was measured using a Wallac Victor 2 Counter Plate Reader (both from
Perkin Elmer Life and Analytical Sciences). Specific lysis was calculated by a formula:
(experimental lysis count - spontaneous lysis count) / (maximum lysis count [by lysis
buffer] - spontaneous lysis count) times 100%. In HLA inhibition experiments, target
cells were coated with 10 ug/mL anti-pan–major histocompatibility complex (MHC;
LEAF clone W6/32, BioLegend, San Diego, CA) antibody for 30 minutes at 37°C prior
to co-culture with the effector cells. For NKG2D blocking assays, primary NK cells were
coated with 20 ug/ml anti-NKG2D blocking antibody (clone 1D11, BD Biosciences) for
30 minutes at 37°C prior to co-culture with the target cells.
Drug Treatments
Cell lines were treated with various concentrations of histone deacetylase
inhibitor sodium valproate (Depacon, Hikma Farmaceutica, Portugal). MICA expression
was observed 2 days after sodium valproate treatment for all cell lines except NB-1691
and CHLA-255 that were analyzed 4 days post treatment. For treatment with proteasome
inhibitor Bortezomib (Velcade, Millenium Pharmaceuticals, Cambridge, MA), various
concentrations were used and MICA was analyzed 16 hours after treatment. The
optimum concentration for both drugs was determined by analysis of cell viability using
trypan blue staining.
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Quantification of MICA Transcripts by Real-Time PCR
Total RNA was isolated from cell lines before and after sodium valproate
treatment using the RNeasy Plus kit (Qiagen, Valencia, CA). Two μg of total RNA was
reverse transcribed using the cDNA synthesis Vilo kit (Invitrogen) according to the
manufacturer’s protocol. Real-time PCR analysis was performed using ABI 7900HT
sequence detection and a Fast SYBR Green PCR master mix system (Applied
Biosystems, Foster City, CA) according to the manufacturer's specification. Samples (50
ng of cDNA per well) were performed in duplicate in 20μl reactions with 200nM
primers. The real-time PCR cycling conditions were 95ºC for 20 sec; 40 cycles at 95ºC
for 1 sec and 60ºC for 20 sec; and then extension at 72ºC for 3 mins followed by a
dissociation phase. GAPDH was used as an internal control. Primers used were MICA
forward 5’-ACA ATG CCC CAG TCC TCC AGA-3’, MICA reverse 5’-ATT TTA GAT
ATC GCC GTA GTT CCT-3’, GAPDH forward 5’-GCC ATC AAT GAC CCC TTC
ATT-3’ and GAPDH reverse 5’-TTG ACG GTG CCA TGG AAT TT-3’. MICA mRNA
expression was normalized with that of GAPDH and compared to untreated cells.
CD107a Degranulation Assay
NK cells pretreated overnight with 10 U/mL of IL-2 were cocultured with target
cells at a ratio of 1:2 in the presence of FITC-conjugated anti-CD107a antibody (H4A3,
BD Biosciences). Monensin (BD Biosciences) was added to the cells 1 hour after
coculture. After 4 hours, the cells were harvested and stained with anti-CD3 and antiCD56 antibodies to determine the percentage of CD107a+ NK cells by flow cytometry.
Anti-NKG2D and anti-HLA-ABC antibodies were also used in some experiments.
ELISA
For detection of soluble MICA (sMICA), plates were coated overnight with
capture anti-MICA monoclonal antibody AMO1 (BamOmaB, Germany) at 2 μg/ml in
PBS, blocked with 3% BSA for 2 hours at 37°C and washed with buffer consisting of 1X
TBS + 0.1% Tween 20 (TBST). Afterward 100 uL of standard (recombinant human
MICA-Fc chimera, R&D Systems) or samples (72 hour cell culture supernatants) diluted
in 3% BSA + 0.1% TBST were added to the plates and incubated for 2 hours at room
temperature. After incubation, plates were washed and the detection antibody BAMO3
(BamOmaB) at 1 μg/ml in 3% BSA + 0.1% TBST was added for 2 hours at 37°C. Plates
were then washed and anti-mouse IgG2a-HRP (SouthernBiotech, Birmingham, AL)
diluted 1:8000 in 3% BSA + 0.1% TBST was added for 1 hour at room temperature.
Plates were then washed and developed using the Tetramethylbenzidine Peroxidase
Substrate System (eBioscience, San Diego, CA). The absorbance was measured at 405
nM using a Wallac Victor 2 Counter Plate Reader.

19

Immunoprecipitation and Western Blotting
MICA immunoprecipitation was carried out using the Pierce Classic IP kit
(Thermo Scientific, Rockford, IL) according to the manufacturer’s instructions. Lysates
were prepared by re-suspending cell pellets in IP lysis buffer (25mM Tris-HCl, 150mM
NaCl, 1mM EDTA, 1% NP-40, 5% glycerol, pH 7.4) with protease inhibitor (Sigma).
Cells were lysed at 4°C for 5 min and centrifuged at 13,000 × g for 10 min. Protein
concentrations were determined using the Pierce BCA Protein Assay Kit (Thermo
Scientific) according to the manufacturer’s protocol. Cell lysates containing 800ug of
protein were pre-cleared using the control agarose resin. Pre-cleared lysates were
incubated with 6μg anti-MICA/B antibody BAMO3 (MBL International Corporation,
Woburn, MA) or 6ug mouse IgG2a isotype control (Abcam, Cambridge, MA) at 4°C
overnight. Immune complexes were captured using Protein A/G Plus Agarose, washed
with IP lysis buffer and eluted in sodium dodecylsulfate gel electrophoresis (SDS-PAGE)
sample buffer. Samples were resolved by SDS-PAGE and transferred to nitrocellulose
membranes. Membranes were kept in blocking buffer (LI-COR, Lincoln, NE) for 1 hour
at room temperature, incubated with goat polyclonal anti-human MICA antibody
(AF1300) overnight at 4°C followed by IRDye 680LT conjugated donkey anti-goat IgG
(LI-COR). Following incubation, membranes were washed and scanned at 700 nm with
the Odyssey infrared imaging system (LI-COR).
Immunofluorescence Confocal Microscopy
Cells were fixed in 3.7% paraformaldehyde in PBS for 15 mins and permeabilized
in 0.1% Triton X-100 for 10 mins. After blocking in PBS with 3% BSA and 0.02%
Triton X-100, cells were incubated with MICA antibody AMO1 (BamOmaB) diluted
1:100 in PBS with 3% BSA for 1 hour. Unbound primary antibody was washed out by
rinsing three times in PBS. Bound antibody was detected with AlexaFluor 594 goat antimouse IgG (Molecular Probes, Grand Island, NY) diluted 1:200 in PBS with 3% BSA.
After unbound secondary antibody was washed out by rinsing three times in PBS, cells
were mounted on glass slides using Prolong Gold Antifade reagent with DAPI
(Molecular Probes). For co-localization experiments, fixed and permeabilized cells were
incubated with organelle markers diluted in blocking buffer for 1 hour after MICA
staining. FITC labeled antibodies to EEA1 (diluted 1:100), GM130 (diluted 1:10) and
LAMP1 (diluted 1:10) were obtained from BD Biosciences and unconjugated anticalnexin antibody (diluted 1:200) was obtained from Abcam. Bound calnexin antibody
was detected by FITC-conjugated anti-rabbit IgG (Jackson Immunoresearch, West
Grove, PA). All procedures were performed at room temperature. Images were acquired
on a Zeiss 510 Meta multi-photon confocal microscope (Zeiss, Oberkochen, Germany).
Analysis was performed using LSM510 META software (Zeiss).
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Statistical Analysis
In all experiments, statistical significance was calculated using student’s t-test.
For cluster plot analysis, mean ligand expression score and mean lysis were calculated as
below:
Mean ligand expression score
x
x
x
x

Expression = Ligand mean fluorescence intensity (MFI) - background MFI
Expression mean = natural log (Mean (expression in experiment 1+ expression in
experiment 2+ expression in experiment 3 ) +1)
Expression mean weight = Expression mean X weight* for each ligand
Mean ligand expression score = sum of Expression mean weight within a cell line

*Weight was calculated as spearman correlation coefficients between each ligand
expression and corresponding percentage of cell lysis (Table 3-1).
Mean lysis
Mean lysis = natural log (mean (lysis at experiment 1) + (lysis at experiment 2) +
(lysis at experiment 3) +1)
After determining the mean ligand expression score and mean lysis, K-means
clustering method was applied to the data from 20 cancer cell lines. In this algorithm, “n”
observations are partitioned into “k” clusters in which each observation belongs to the
cluster with the nearest mean. Mathematically, analysis of x variables presents 2x
possibilities. Since 2 variables were analyzed, “k” was fixed at 4 in our cluster analysis.
The 4 phenotypes hypothesized are shown in Table 3-2.
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Table 3-1.

Weight for each NKG2D ligand
NKG2D ligand
MICA
MICB
ULBP1
ULBP2
ULBP3

Table 3-2.

Weight
0.2616643
0.5038257
0.5758988
0.4181352
0.1212418

Four possible phenotypes in our cancer cell spectrum

Group
1
2
3
4

Level of NKG2D ligand expression
High
Low
High
Low
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NK susceptibility
High
Low
Low
High

CHAPTER 4.

RESULTS

Heterogeneity in NK Susceptibility and NKG2D Ligand Expression in Cancer Cell
Lines
We first sought to determine the susceptibility of cancer cell lines to NK cell
lysis. Resting primary NK cells from 3 healthy donors were co-cultured with different
target cancer cells in an effector:target ratio of 20:1. A clear heterogeneity was observed
in the cancer cell susceptibility to NK cells. Only one third of the cancer cell lines were
susceptible to NK killing (defined as specific lysis > 10%, Figure 4-1A). Leukemic cell
lines U937, K562, and Jurkat had a high percentage of specific lysis while another
leukemia cell line MOLT-4, lymphoma cell line L-428 and colon carcinoma cell line
HCT116 were moderately NK sensitive. Two thirds of the cancer cell lines exhibited
resistance to NK killing with less than 5% specific lysis.
We determined the surface expression of NKG2D ligands MICA, MICB, ULBP1,
ULBP2 and ULBP3 on the cancer cell lines. By flow cytometry we quantified surface
expression in terms of mean fluorescence intensity (MFI). The ligand expression was
found to be heterogeneous in our cancer cell line spectrum (Figure 4-1B, C, D, E and F).
For MICA, high levels of expression were observed on HeLa, RD, L-428 and K562 and
minimal levels on the other 16 cell lines (Figure 4-1B). For MICB, high level of
expression was observed on K562 and low levels on Jurkat, HeLa and MOLT-4cell lines
(Figure 4-1C). For ULBP1, high expression was observed on MV4-11 and low levels on
U937, Jurkat, K562, HCT116 and HDLM-2 (Figure 4-1D). For ULBP2, high expression
was seen on HeLa, Jurkat, and CAL 27, and low levels on HDLM-2, HCT116, L-428,
K562, U937 and MOLT-4 (Figure 4-1E). Lastly, for ULBP3, very high expression was
observed on L-428, moderate expression on RD, HDLM-2, HCT116, and CAL 27, and
low levels on K562, HeLa, L-540, MV4-11 and Daudi (Figure 4-1F). Collectively, the
top 5 cell lines that had the highest cumulative levels of the 5 NKG2D ligands were
K562, HeLa, Jurkat, L-428 and HCT116.
Level of NKG2D Ligand Expression Usually (but Not Always) Correlates with NK
Susceptibility
In order to determine whether NKG2D ligand expression is directly proportional
to NK susceptibility of tumor cells, the correlation between the 2 parameters was
analyzed by K-means clustering algorithm and Wilcoxon rank-sum tests. Cluster analysis
revealed 3 phenotypic clusters (Figure 4-2). Group 1 phenotypic cluster included U937,
K562, Jurkat, MOLT-4, HCT116 and L-428. Compatible with our hypothesis that the
higher the level of NKG2D ligand expression, the greater the susceptibility to NK cells,
these group 1 cancer cell lines had abundant NKG2D ligand expression and high
susceptibility to NK cells. Also in line with the hypothesis are the group 2 cancer cells
with low NKG2D ligand expression and low NK susceptibility. This group included the
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Figure 4-1. Heterogeneity in NK susceptibility and NKG2D ligand expression of
cancer cell lines.
(A) Percentage lysis of 20 cancer cell lines by resting primary NK cells co-cultured for 2
hr at E:T ratio of 20:1. Data represents mean lysis ± SEM from 3 independent
experiments. Surface expression of (B) MICA, (C) MICB, (D) ULBP1, (E) ULBP2 and
(F) ULBP3 on 20 cancer cell lines was determined by flow cytometry and expressed as
mean fluorescence intensity (MFI). Data represents mean ± SEM of from 3 independent
experiments.
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Figure 4-2. Level of NKG2D ligand expression usually (but not always) correlates
with NK susceptibility.
(A) Cluster plot of four distinct phenotypes in the cancer cell spectrum. Level of NKG2D
ligand expression represents mean ligand expression score as stated in materials and
methods. Level of NK susceptibility denotes mean lysis. (B) Mean ligand expression
score for groups 1, 2 and 3. (C) Mean percentage of lysis for groups 1, 2 and 3. Bars
represent median values. Data are the mean ± SEM from 3 independent experiments.
**, p<0.01, ***p<0.001 as compared with group 1.
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cell lines NB-1691, CHLA-255, RS4;11, SEM, L-540, L-591, Hs 445, RPMI 6666 and
Daudi. In contrast to the above 2 groups, group 3 cell lines had an unexpected phenotype
of low NK sensitivity despite a high NKG2D ligand expression. Group 3 included HeLa,
MV4-11, RD, CAL 27 and HDLM-2. Notably, none of the cell lines in our cohort
exhibited a group 4 phenotype i.e. low NKG2D ligand expression and high NK
susceptibility, supporting our primary hypothesis that NKG2D ligand expression is
essential (though at times insufficient) for NK cell recognition.
NK Sensitivity of Group 1 Cells Involves the NKG2D Pathway
To validate that the high NK susceptibility of group 1 cells was due to the
presence of NKG2D ligands on their surface, we performed NK cytotoxicity assay in the
presence of NKG2D blocking antibody. Primary resting NK cells were incubated with
BATDA labeled group 1 cell lines as targets in an effector: target ratio of 20:1 in the
presence or absence of NKG2D blocking antibody. We observed a significant reduction
in the NK lysis of group 1 cancer cells when the NKG2D receptor was blocked on NK
cells (Figure 4-3). More than 50% loss of specific lysis was seen in the presence of the
NKG2D blocking antibody, suggesting that the NKG2D pathway contributed
significantly to the NK sensitivity of the group 1 cancer cells.
Pediatric Leukemia Patients Show a Group 2 rather than Group 1 Phenotype
Since NK transplantation is commonly used for the treatment of childhood
leukemia, we hypothesized that pediatric leukemia exhibit a group 1 phenotype.
Surprisingly, negligible levels of surface NKG2D ligands were observed on 8 patient
samples when compared to K562 (Figure 4-4). One of the patient samples (represented
as ▲) showed low level of surface expression of MICA, ULBP1, ULBP2 and ULBP3
with low % lysis. Another patient sample (represented as ○) expressed high level of
ULBP3 on the cell surface with NK lysis almost comparable to that of K562. As
expected, the 8 leukemia samples that did not express NKG2D ligands on their cell
surface exhibited NK resistance. Taken together, the majority (90%) of pediatric
leukemia patients exhibited a group 2 phenotype with NK resistance and absence of
NKG2D ligands, and only 1 patient (10%) showed a group 1 phenotype (high NK
susceptibility and NKG2D ligand expression).
Ectopic Expression of MICA Overcomes NK Resistance
In order to test our hypothesis that the absence of NKG2D ligand expression was
solely responsible for NK resistance in the group 2 cells, we ectopically expressed MICA
on MLL cell line RS4;11, lymphoma cell line Daudi and neuroblastoma cell line NB1691. We created stable MICA expressing lines via retrovirus transduction and confirmed
surface expression of MICA on the three cell lines 72 hours post transduction by flow
with the cytometry (Figure 4-5A). Using these cells lines as targets, we performed NK
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Figure 4-3. NK cytotoxicity of group 1 cells involves the NKG2D pathway.
Mean percentage specific lysis of group 1 cell lines by primary resting NK cells in the
absence (□) or presence (■) of anti-NKG2D blocking antibody. Effector and targets were
cocultured at 20:1 ratio and lysis was evaluated by BATDA assay. Data are mean %
specific lysis ± SEM from 3 independent experiments. *, p<0.05 when compared to
untreated cells.
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Figure 4-4. NKG2D ligand expression and NK susceptibility of leukemia patients.
Surface expression of NKG2D ligands (A) MICA, (B) MICB, (C) ULBP1, (D) ULBP2
and (E) ULBP3 on K562 (●) and leukemia patient samples (■). Each (●) represents one
experimental data point for K562. The outliers in patient samples are represented as (▲)
and (○). Bars represent median mean fluorescence intensity of NKG2D ligands. (F) Mean
percentage lysis of K562 and patient blasts by NKL cell line at E:T ratio 20:1. Bars
represent median lysis. ***p<0.001.
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Figure 4-5. Ectopic expression of MICA overcomes NK resistance in group 2
cancer cells.
(A) Histogram of MICA surface expression on group 2 cancer cell lines RS4;11, Daudi
and NB-1691 stably transduced with empty vector (black line) or full length MICA (red
line). Isotope control was presented as shaded histograms. (B) Cytotoxicity of NKL cell
line against MICA transduced cell lines (■) and empty vector transduced cell lines (○).
Data represents mean % lysis ± SEM from 3 independent experiments. *, p<0.05
compared to cell line transduced with empty vector.
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cytotoxicity assays using the NKG2D dependent effector cell line NKL. NK cytotoxicity
assays revealed a significantly higher lysis of the MICA expressing cell lines when
compared to the vector alone controls (Figure 4-5B).
Low Levels of MICA Surface Expression in Group 2 Cancer Cells Were in Part due
to Transcription Silencing
To understand the mechanism of low MICA surface expression in group 2 cancer
cells, we determined the mRNA levels by real time PCR. We found significantly lower
levels of MICA transcripts in the group 2 cell lines when compared to group 1 cell line
K562 (Figure 4-6). Notably, the neuroblastoma cell lines NB-1691 and CHLA-255 had
no detectable MICA mRNA. Among the group 2 cancer cell lines, lymphoma line L-591
had the highest levels of mRNA transcripts, compatible with the highest surface protein
expression among this group of cell lines.
Histone Deacetylase Inhibitors Can Upregulate MICA mRNA and Surface
Expression in Neuroblastoma Cell Lines
Epigenetic mechanisms like histone deacetylation have been implicated in
repression of gene transcription [152]. Altered histone deacetylase (HDAC) activity has
been identified in several cancers [153, 154]. Hence, we investigated whether histone
deacetylation was responsible for the low levels of MICA mRNA in the group 2 cancer
cell lines. We observed a significant upregulation in MICA mRNA in the neuroblastoma
cell lines NB-1691 and CHLA-255 post treatment with histone deacetylase inhibitor
(HDACi) sodium valproate (Figure 4-7A). Flow cytometry showed a corresponding
increase in MICA expression on the neuroblastoma cell lines (Figure 4-7B). To
investigate NK susceptibility of the HDACi treated cells, we performed NK cytotoxicity
assay on NB-1691 cells four days post treatment with 5mM sodium valproate. HDACi
treated NB-1691 cells showed significantly higher NK lysis as compared to the untreated
cells. The increase in NK susceptibility was completely abolished in the presence of antiNKG2D blocking antibody (Figure 4-7C).
Histone Deacetylase Inhibitor Treatment Only Marginally Upregulated MICA
mRNA and Surface Protein in the Leukemia and Lymphoma Group 2 Cancer Cells
For the resistant leukemia and lymphoma cell lines in our group 2 cluster, we
determined if HDAC inhibitor treatment could upregulate MICA expression as in
neuroblastoma. We observed only a marginal increase in the transcript levels in most of
the cell lines, except Hs 445 and Daudi, 48 hours after sodium valproate treatment
(Figure 4-8A). In accordance with the mRNA increase, only Daudi and Hs 445 showed
slight increase in surface MICA expression post HDAC inhibitor treatment while the
remaining group 2 lines showed negligible increase (Figure 4-8B). This marginal
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Figure 4-6. Low level of MICA transcripts in group 2 cancer cells.
MICA mRNA expression in group 2 cancer cells (■) normalized to GAPDH and relative
to K562 (□, taken as 1). Data are mean ±SEM from 3 independent experiments.
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Figure 4-7. HDAC inhibitor treatment upregulates MICA mRNA and protein
levels on neuroblastoma cell lines and increases their susceptibility to NK cells.
(A) Relative MICA mRNA levels in untreated (white) and 5mM treated NB-1691(black)
or 2.5mM treated CHLA-255 (black) four days after treatment. Data are mean mRNA
expression ± SEM in treated cells compared to untreated cells from 3 independent
experiments. (B) Histograms of surface MICA on untreated (black) and sodium valproate
treated (red) neuroblastoma cells. Isotype control was presented as shaded histograms.
Data are representative of 4 experiments. (C) Cytotoxicity of primary NK cells against
untreated (white), sodium valproate treated (black) NB-1691 cells and sodium valproate
treated NB-1691 cells in the presence of anti-NKG2D blocking antibody (grey). Data are
mean % lysis ± SEM from 3 independent experiments. *, p<0.05; **, p<0.01;
***p<0.001.
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Figure 4-8. Effect of HDAC inhibitor treatment on MICA mRNA and protein
levels in the remaining group 2 cancer cells.
(A) Relative MICA mRNA levels in untreated (white) and sodium valproate treated
(black) group 2 cancer cells. Data are mean MICA mRNA ±SEM in the treated cells
compared to untreated cells from 3 independent experiments. (B) Histograms of MICA
surface expression on untreated cells (black line) and sodium valproate treated cells (red
line) 48 hours after treatment. Isotype control was presented as shaded histogram. Data
are representative of 4 independent experiments. (C) Cytotoxicity of primary NK cells
against untreated (white), sodium valproate treated (black) and sodium valproate treated
group 2 cells cells in the presence of anti-NKG2D blocking antibody (grey). Data are
mean % lysis ± SEM from 3 independent experiments. *, p<0.05.
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upregulation in MICA was mirrored by a marginal upregulation in the NK lysis of the
group 2 cancer cells (Figure 4-8C).
Group 2 Cells Express Low Levels of Intracellular MICA
To determine whether the low mRNA quantity in group 2 leukemia and
lymphoma lines corresponded with low levels of intracellular MICA protein, we
determined the amount of intracellular MICA using confocal microscopy (Figure 4-9).
As expected, the level of intracellular MICA protein was much lower in the group 2 cells
than in the group 1 cell line K562. In K562, relatively large amount of surface and
intracellular MICA could be visualized.
Shedding of MICA Is Not Responsible for the Absence of Surface MICA in Group 2
Cancer Cell Lines
Having observed low amount of intracellular and surface MICA in our group 2
cluster, we investigated whether shedding of NKG2D ligands collaborated with
transcription silencing [85, 93]. In all group 2 cell lines, we could not detect soluble
MICA in the culture supernatants by ELISA (Figure 4-10). Collectively, these results
indicate that shedding of MICA did no contribute to the low surface levels in our group 2
cancer cell lines, but rather the mechanism is related to transcription repression.
The Small Amount of MICA in Group 2 Cells Is Retained in the Endoplasmic
Reticulum
With high resolution confocal microscopy we next investigated the subcellular
localization of MICA with markers for endoplasmic reticulum (calnexin), golgi complex
(GM130), lysosomes (LAMP1) and endosomes (EEA1). Co-localization of MICA
(shown in red) with the ER marker calnexin (shown in green) was observed (yellow
staining) in all group 2 cell lines including RS4;11, Hs 445 and RPMI 6666. In addition,
co-localization of MICA with calnexin was also observed in an AML patient sample that
was negative for cell surface expression of MICA (Figure 4-11A). Clear points of colocalization (indicated by white arrows) were observed in a single cell image of RS4;11
(Figure 4-11B). Confocal microscopy in RS4;11 cells with other subcellular organelle
markers revealed no significant co-localization of MICA with the golgi complex marker
GM130 (Figure 4-11C), early lysosome marker LAMP-1 (Figure 4-11D) and early
endosome marker EEA1 (Figure 4-11E).
Treatment with Proteasome Inhibitor Increases Surface Expression of MICA
With knowledge of MICA being retained in the ER, we determined whether their
surface expression could be restored using proteasome inhibitor bortezomib. MICA
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Figure 4-9. Presence of intracellular MICA protein in group 2 cells.
Immunofluorescence images of differential interference contrast (DIC), DAPI (blue),
MICA (red) and merge of the blue and red channels in group 1 cell line K562 and the
indicated group 2 lines. Results are representative of 3 independent experiments.
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Figure 4-10. MICA is not shed by group 2 cancer cell lines.
Level of soluble MICA in the supernatants of group 2 cell lines. Data represent mean
soluble MICA (pg/mL) ± SEM from 2 independent experiments. Red line represents the
background level from medium alone control. The detection limit of the ELISA was 50
pg/mL to 6250 pg/mL.
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Figure 4-11. MICA is retained in the endoplasmic reticulum.
(A) Confocal microscopy images showing co-localization of MICA (red) with ER marker
calnexin (green) in the indicated group 2 cell lines and in a patient sample. Results are
representative of 2 independent experiments. (B) Single cell image RS4;11 cell showed
MICA co-localization with calnexin. White arrows show points of colocalisation.
Confocal microscopy images showing no significant co-localization of MICA with other
compartment markers including (C) Golgi marker GM130; (D) lysosome marker LAMP1
and (E) early endosome marker EEA1 in RS4;11 cells.
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Figure 4-11. (Continued).
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immunoprecipitation revealed an increase in intracellular MICA in group 1 cell line
HCT116 and group 2 cell lines L-591 and RS4;11, which in turn increased the surface
expression of MICA (Figures 4-12A and B). The effect of bortezomib was independent
of the background expression of MICA since it upregulated MICA in the group 1
HCT116 cells that show surface MICA and also on the group 2 cells that have low to
negligible levels of surface MICA. We further investigated whether the increase in
surface MICA could increase NK susceptibility. NK cytotoxicity assays revealed that L591 cells had a significantly higher NK lysis post bortezomib treatment. To validate that
the augmented susceptibility was due to the NKG2D pathway, we neutralized the
receptor on NK cells using anti-NKG2D blocking antibody. When anti-NKG2D blocking
antibody was applied, a significant reduction in NK susceptibility of L-591 cells was
observed (Figure 4-12C).
NK Resistance of Group 3 Cell Lines Was Not due to PI-9 Overexpression
We then investigated the mechanisms of NK resistance in the group 3 cell lines
despite high level of NKG2D ligand expression. It is well known that tumors can resist
cytotoxic T lymphocyte mediated killing by expression of the serine protease inhibitor
protease inhibitor 9 (PI-9) which inactivates granzyme B [155]. Hence, we considered
whether overexpression of protease inhibitor 9 was a possible mechanism for NK
resistance in our group 3 cell lines. The NK resistant group 3 cancer cells showed similar
levels of PI-9 expression as the NK sensitive group 1 cells (Figure 4-13). Positive control
YT-Indy NK cells showed high levels of intracellular PI-9 by flow cytometry. This
indicated that overexpression of PI-9 was not a contributing factor to the NK resistance in
the group 3 cells.
KIR Inhibition Overrides NKG2D Activation in Group 3 Cells
According to the rheostat concept, inhibitory signals overriding the activating
signals can lead to NK resistance of tumors [24, 156]. To determine if this was indeed the
mechanism of resistance in our group 3 cells, we examined the expression level of KIR
inhibitory ligands HLA-ABC on our group 3 cell lines. All cancer cell lines showed high
level of KIR inhibitory ligands on the cell surface (Figure 4-14A). When we performed
NK cytotoxicity assays with primary NK cells against the group 3 lines in the absence or
presence of anti-HLA-ABC blocking antibody, blockade of the inhibitory signals resulted
in a significant increase in NK susceptibility of HeLa, HDLM-2, CAL 27, and MV4-11.
When saturating amounts of the anti-NKG2D blocking antibody was applied, the
augmented NK sensitivity was considerably reduced suggesting that the increased NK
susceptibility was due to the activating signals from the NKG2D pathway in K562 and
HDLM-2 (Figure 4-14B). However, RD rhabdomyosarcoma cells did not show increased
NK sensitivity in the presence of the anti-HLA antibody.
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Figure 4-12. Treatment with proteasome inhibitor increases surface expression of
MICA.
(A) MICA immunoprecipitation showing MICA levels in the absence (-) or presence (+)
of bortezomib 16 hours after treatment in the indicated cell lines. Data are representative
of 2 experiments. (B) Histograms of surface MICA expression in untreated cells (black
line) and bortezomib treated cells (red line). Isotype control was presented as shaded
histograms. Data are representative of 3 experiments. (C) NK susceptibility of untreated
or 25nM bortezomib treated L-591 cells in the presence of isotype control (white) or antiNKG2D antibody (black). Data are mean % lysis ± SEM from 3 independent
experiments. *, p<0.05; **, p<0.01.
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Figure 4-13. No significant difference in PI-9 levels between group 1 and group 3
cell lines.
Bars represent mean PI-9 MFI in group 1 and group 3 cell lines. Data are mean MFI
±SEM from 3 independent experiments. Positive control is YT-Indy cells.
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Figure 4-14. KIR inhibition overrides NKG2D activation in group 3 cells.
(A) Expression of inhibitory ligands HLA-ABC (black line) on the indicated group 3 cell
lines. Isotype control was presented as shaded histogram. Data are representative of 2
independent experiments. (B) NK susceptibility of group 3 cells lines untreated (blue
line), treated with anti- HLA-ABC blocking antibody (red line), treated with anti-HLA
blocking antibody+anti-NKG2D blocking antibody (green line) to NK cells at E:T ratios
5:1, 10:1, 20:1. Data are mean % lysis ± SEM from 3 independent experiments.
*, p<0.05; **, p<0.01; ***p<0.001.
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RD Cells Cannot Degranulate NK Cells
Since blockade of KIR-HLA interaction did not augment NK sensitivity of RD
cells, we determined whether RD cells might at least activate NK cells through NKG2D.
We observed that the NK sensitive group 1 cell line K562 could trigger degranulation in
42% of NK cells while the resistant group 3 lines HDLM-2 and RD could trigger
degranulation in less than 10% of NK cells. In the presence of anti-HLA-ABC blocking
antibody, K562 did not show an increase on CD107a+ NK cells as it lacks MHC class I
on its surface; however HDLM-2 showed a significant increase in CD107a+ NK cells. In
contrast, RD cells showed no increase in NK degranulation. When saturating amounts of
anti-NKG2D antibody was applied, the percentage of CD107a+ NK cells was
significantly reduced in K562 and HDLM-2 cell lines’ suggesting that NK activation was
through the NKG2D pathway. No significant loss of NK degranulation was observed in
RD cells (Figure 4-15). Taken together, these data suggested that the resistance of RD
cells was not due to KIR-HLA inhibition, but inability to activate NKG2D despite high
levels of NKG2D ligand expression.
NK Resistant RD Cells Expressed Low Levels of ICAM-1
We then hypothesized that the NK resistance in RD cell line might be due to low
levels of adhesion molecule ICAM-1, which is essential for immune-synapse formation.
Flow cytometry revealed that ICAM-1 levels on the RD cells are indeed significantly
lower than other group 3 cell lines (Figure 4-16).
NKG2D Pathway Can Be Modulated in Patient Samples
We then extended our investigation from cancer cell lines to fresh patient
samples. We carried out analyses on two representative pediatric leukemia patient
samples. Blasts from a patient with MLL rearranged leukemia (patient 001) had low
NKG2D ligand expression on cell surface representing group 2 cells, while those from an
AML patient (patient 002) had high NKG2D ligand expression with low NK
susceptibility representing group 3 cells (Figure 4-17A and E).
Based on our previous findings on the NK resistance mechanisms employed by
group 2 cell lines, we determined whether the NKG2D ligand expression on the patient
001 blasts could be modulated by treatment with HDACi sodium valproate and
proteasome inhibitor bortezomib. Treatment of patient 001 blasts with sodium valproate
or bortezomib resulted in a marked increase in the surface MICA and ULBP2 ligands
while MICB and ULBP1 showed no change in surface expression. MICA and ULBP2
showed a higher increase in the sodium valproate treated blasts when compared to the
bortezomib treated blasts (Figure 4-17A and B). We observed a 2.1 fold increase in the
percentage of degranulated (CD107+) NK cells post treatment with sodium valproate
using the CD107 assay and a 1.4 fold increase in CD107+ NK cells post bortezomib
treatment of the patient blasts (Figure 4-17C top panel).
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Figure 4-15. RD cells cannot degranulate NK cells.
Percentage of CD107a+ NK cells in the presence of target cells alone (white), target cells
coated with anti-HLA-ABC (black), target cells coated with anti-HLA-ABC and NK cells
coated with anti-NKG2D (grey). Data are mean percentage of CD107a+ NK cells ± SEM
from 2 independent experiments. *, p<0.05.
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Figure 4-16. Low ICAM-1 expression on RD cells.
Surface expression of ICAM-1 on group 3 cell lines. Data are mean MFI ± SEM from 2
independent experiments.
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Figure 4-17. Modulation of NKG2D pathway in pediatric leukemia samples.
A) Surface expression of the indicated NKG2D ligands on patient 001 blasts before
(black line) and after 48 hour treatment with 2.5mM sodium valproate (red line). (B)
Surface expression of the indicated NKG2D ligands on untreated patient 001 blasts
(black line) and after 16 hour treatment with 10nM bortezomib (red line). Isotype
controls were presented as shaded histograms. (C) NK degranulation in untreated and
drug treated patient 001 blasts in the absence or presence of anti-NKG2D antibody
indicated as percentage of CD107 positive cells. (D) NK susceptibility of untreated or
drug treated patient 001 blasts at 20:1 E:T ratio in the absence (white) or presence (black)
of anti-NKG2D antibody. (E) Surface NKG2D ligand expression on patient 002 blasts.
(F) Susceptibility of patient 002 blasts to primary NK cells at 20:1 E:T ratio. Data are
mean % lysis ± SEM from 3 different donors. ***p<0.001.
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Figure 4-17. (Continued).
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The significant reduction in NK degranulation in the presence of blocking antiNKG2D antibody validated that the increase in NK activation post drug treatment was
due to the NKG2D pathway (Figure 4-17C bottom panel). Higher NK susceptibility of
the sodium valproate treated and bortezomib treated blasts was observed when compared
to the untreated cells. The bortezomib treated blasts were however killed to a lesser
extent when compared to the HDACi treated blast cells (Figure 4-17D). The percentage
of NK degranulation and susceptibility of patient 001 blasts was in accordance with the
level of increase in surface MICA and ULBP2 post treatment with HDACi and
bortezomib.
Blasts from patient 002 had a high NKG2D ligand expression on their surface
(Figure 4-17E) and showed only 10% specific lysis, indicating a NK resistant group 3
phenotype. Based on our previous observations of KIR inhibition overriding NKG2D
activation, we treated patient 002 blasts with pan anti-HLA-ABC blocking antibody. In
the presence of the HLA blocking antibody, a significant increase in the NK
susceptibility of the blasts was observed. This increased NK lysis was also significantly
diminished in the presence of the anti-NKG2D blocking antibody (Figure 4-17F).
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CHAPTER 5.

DISCUSSION

Despite intensive therapy and new chemotherapeutic agents, a high incidence of
chemo-resistance is observed in hematological malignancies and solid tumors [157, 158].
Investigations in the past decade have focused on inventing better immune based
therapies, given their non-cross resistance and less overlapping side effects with current
therapies [159, 160]. NK cell transplantation is being increasingly used for treatment of
chemo-resistant cancers, because it has the potential to provide anticancer effects without
GVHD or organ toxicity [161]. However, NK resistance of cancers (if prevalent) would
undermine the efficacy of NK transplantation. In this study we showed that 1) the
majority of cancer cell lines and pediatric patient samples are resistant to NK cell lysis, 2)
NK resistance is commonly due to lack of NKG2D activation or due to inhibitory signals
overriding NKG2D activation, and 3) NKG2D pathway can be modulated to overcome
NK resistance of cancer. In addition to demonstrating that NKG2D is the primary
pathway in NK susceptible tumors, our comprehensive study also reinforces the key
therapeutic paradigm that the NKG2D pathway can be manipulated to increase NK
susceptibility of tumor cells thereby improving the outcomes of NK transplantation.
NK Resistance Is Predominant in Cancer
The occurrence of malignancies resulting via tumor escape may be due to
defective NK cells or inherent features of tumor cells [162]. Elucidating these aspects
regulating NK interaction with tumor cells is important to understand the role of NK cells
in the control of cancer as well as their potential as a means of immunotherapy. Although
various groups have investigated certain aspects of NK lysis of tumor cells [162-166], the
prevalence and mechanism of NK resistance in cancer is still not well elucidated. In our
study, we conducted a comprehensive analysis to determine the occurrence and frequency
of NK resistance in cancer. Contrary to the above mentioned research groups that focused
their study on a particular cancer type or limited number of cell lines, we analyzed NK
susceptibility in a broad spectrum of 20 cancer cell lines representing various different
cancer types including chronic myeloid leukemia (K562), T-cell acute lymphoblastic
leukemia (MOLT-4, Jurkat), acute myeloid leukemia (U937), mixed lineage leukemia
(SEM, RS4;11, MV4-11), Burkitt’s lymphoma (Daudi), Hodgkin’s lymphoma (L-540, L591, Hs 445, RPMI 6666, L-428, HDLM-2), colon carcinoma (HCT116),
rhabdomyosarcoma (RD), cervical carcinoma (HeLa), head and neck squamous
carcinoma (CAL 27) and neuroblastoma (NB-1691, CHLA-255). Our results indicate a
very high prevalence (70%) of NK resistance with majority of the cancer cell lines
exhibiting less than 5% specific lysis. NK resistance was not associated with any
particular cancer type. In fact, while some leukemia lines like K562, U937, Jurkat and
MOLT-4 exhibited high NK susceptibility some others like MV4-11, SEM and RS4;11
showed NK resistance. Of the 6 lymphoma lines, only one cell line L-428 showed high
NK lysis. Similarly, only one of 6 solid tumor cell lines (HCT116) was susceptible to NK
killing. Collectively, NK resistance was commonly observed in both hematological
malignancies and solid tumors.
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Substantial Heterogeneity in NKG2D Ligand Expression and NK Susceptibility
We determined the surface expression of 5 NKG2D ligands on tumor cell lines
and observed a clear heterogeneity in ligand expression. Our results show that MICB and
ULBP1 were the least frequently expressed ligands (20-30%) while MICA, ULBP2 and
ULBP3 were expressed on at least 40-50% of the cell lines. Our study while confirming
the expression of NKG2D ligands on some standard cell lines [167-170] also
demonstrates the pattern of NKG2D ligand expression on additional cell lines
representing Hodgkin’s lymphoma, rhabdomyosarcoma and neuroblastoma. Just as in the
case of NK susceptibility, no specific pattern of ligand expression was observed within
cell lines of a particular cancer type. For example, although both T-ALL cell lines,
expressed NKG2D ligands on their surface, 4 of 5 ligands were expressed on Jurkat while
MOLT-4 showed the presence of only 2. In the MLL rearranged leukemic cell lines,
while MV4-11 showed the presence of surface NKG2D ligands, RS4;11 and SEM had
negligible expression. Thus expression of NKG2D ligands was seen to vary among
tumors of the same histotype. Collectively, we observed differences in the number of
ligands expressed, type of ligands expressed and intensity of expression as quantified by
MFI in our cancer cell lines. These factors could be responsible for the differences in
their NK susceptibility.
In order to correlate NK susceptibility and NKG2D ligand expression, we
analyzed data using the K-means clustering algorithm. Spearman correlation coefficients
between each ligand expression and corresponding percentage of cell lysis showed no
particular ligand to have significant positive correlation with NK susceptibility i.e. there
was no selective advantage in the expression of a specific NKG2D ligand (Table 3-1). In
fact, the diversity in the NKG2D ligand family clearly argues in favor of no particular
ligand being more potent or favorable than the other in inducing NK susceptibility.
Various research groups have clearly shown that the expression of any NKG2D ligand
sensitizes tumor cells to NK killing and there are no known features that distinguish
NKG2D ligands with respect to their function [34, 62].
Although NKG2D-mediated cytotoxicity of cancer cells is well known, the
correlation between ligand expression and NK susceptibility has not been clearly
established. The only paper addressing this was by Pende et al in 2002 where they
reported that NKG2D mediated NK cytotoxicity strictly correlates with the expression
levels and surface densities of its ligands on target cells [167]. However, their
conclusions were based on qualitative analyses of ligand expression with NK
cytotoxicity. For example, T cell lymphoma line H9 was characterized as ULBP2+
ULBP3+ and shown to have high NK susceptibility. In our study, we statistically
analyzed the quantitative measure of NK lysis (in terms of % lysis) and NKG2D ligand
expression (in terms of MFI) and performed a clustering algorithm to group our
phenotypic observations. Cancer cells belonging to groups 1 and 2 showed that level of
NKG2D ligand expression indeed correlates with NK susceptibility. However, our results
also revealed a counterintuitive group 3 phenotype wherein cell lines exhibited NK
resistance despite a high NKG2D ligand expression. This remarkable phenotype was seen
in 25% of the cancer cell lines with no predominance of a particular cancer type.
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Collectively, our results suggest that the level of NKG2D ligand expression usually (but
not always) correlates with NK susceptibility of cancer.
Another striking observation was the absence of cancer cell lines representing a
group 4 phenotype i.e. high NK susceptibility without the expression of NKG2D ligands.
This was in accordance to our hypothesis that NKG2D is the primary pathway for tumor
cell recognition. Because NKG2D-independent NK killing was not observed in our
cancer cell spectrum, our data clearly indicated the importance of this pathway in cancer.
Although NCR-dependent killing has been reported in various NKG2D ligand negative
B-cell leukemic lines and neuroblastoma lines [157, 167, 171], it does not preclude the
role of the NKG2D pathway in these cancers, provided these cell lines could also express
NKG2D ligands with cell stress during transformation.
Furthermore, significant reduction in the lysis of the group 1 cancer cells by
antibody blockade of NKG2D validated a substantial role of this pathway in NK
susceptibility. Almost 80% reduction in NK lysis was observed in most of the group 1
cells, clearly indicating that NKG2D was the primary pathway responsible for NK
sensitivity of these cells. The observation of approximately 20-30 % lysis in the presence
of the NKG2D antibody, however, suggests either incomplete blockade by the antibody
or that other activating signals may simultaneously contribute to the NK susceptibility of
these lines. Synergistic activating signals may be provided by NCRs or co receptors like
DNAM-1 and 2B4 [172-174].
Lack of NKG2D Activation Is Commonly Responsible for NK Resistance
Analysis of blasts from patient samples showed that the majority of the patient
samples exhibit the NK resistant group 2 phenotype. Only one patient exhibited the group
1 phenotype with surface ULBP3 expression resulting in NK susceptibility. With strong
evidence that cancer patients predominantly exhibit a group 2 phenotype, we created
stable MICA expressing cell lines to determine whether the absence of NKG2D ligand
expression was solely responsible for the NK resistance of our group 2 cancer cells. Our
results indicate that transduction-mediated expression of MICA could increase the NK
susceptibility of these resistant cell lines. This effect was not specific to a particular
cancer type as similar observations were made in cell lines representing leukemia,
lymphoma and neuroblastoma (Figure 4-5). Moreover, the dependency on the NKG2D
pathway was validated by using the NKL cell line as effectors. NKL expresses high
levels of NKG2D, but only minimal levels of NCRs and is therefore well suited to study
NKG2D-mediated recognition [34].
In light of the above observations we focused our understanding on mechanisms
employed by group 2 cancer cells to prevent surface expression of NKG2D ligands and
designing strategies to overcome the repression of expression. Our results show that the
majority of group 2 cancer cells express MICA mRNA. However, comparison of their
mRNA levels with that of the group 1 cell line K562 revealed considerably lower level of
MICA transcripts in all group 2 cell lines. In particular, no detectable mRNA was seen in
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the neuroblastoma lines. These results indicated transcription repression of MICA in the
group 2 cancer cells. To further probe into the mechanisms of gene silencing, we
determined whether histone acetylation was responsible for the low mRNA levels.
Chromatin remodeling through histone acetylation has been implicated in the
transcriptional control of genes [175]. Valproic acid has been shown to relieve HDACdependent transcriptional repression by causing hyperacetylation of histones in cultured
cells and in vivo [176]. Our findings clearly demonstrate that HDAC inhibitor sodium
valproate induced MICA mRNA and protein in the group 2 cancer cells albeit at variable
levels.
The neuroblastoma lines including NB-1691 and CHLA-255 showed a marked
increase in MICA mRNA and protein after treatment with HDACi sodium valproate.
Expression of surface MICA resulted in an augmented lysis by NK cells which was
completely abolished by the NKG2D blocking antibody, thus validating the role of this
pathway. Downregulation of NKG2D ligands in neuroblastoma lines and patients has
been reported previously [167, 172, 177] but to our knowledge histone acetylation has
never been implicated for the lack of surface expression of NKG2D ligands in
neuroblastoma. Shedding of MICA has been associated with the lack of surface
expression in neuroblastoma lines [177]. In our study we ruled out this possibility
because soluble MICA was not detected in cell culture supernatants. Our study provides
the first evidence of transcriptional repression of NKG2D ligands in neuroblastoma lines.
In addition to MICA, other NKG2D ligands were also increased at the mRNA and
surface protein levels in the neuroblastoma cell lines after treatment with HDACi sodium
valproate (Figure A-1). Although it is well known that NK lysis of neuroblastoma cells
may be mediated via the NCR and DNAM-1 pathways [157, 171, 178], our study
presents an alternative pathway that is clinically feasible to increase NK susceptibility of
these resistant tumors.
For the group 2 cell lines representing leukemia or lymphoma, treatment with
sodium valproate resulted in marginal upregulation of MICA mRNA. This was mirrored
by a minimal increase in MICA on the surface of these cells and marginal increase in NK
susceptibility suggesting that MICA expression in these lines could only partially be
rescued by histone acetylation. Possibly additional post transcriptional/ post translational
mechanisms may be involved in the regulation of MICA. Importantly, although MICA
expression was only marginally upregulated by sodium valproate, the NKG2D ligand
ULBP2 was induced considerably at the mRNA and surface protein levels in majority of
the group 2 cancer cells (Figure A-2). Similarly, studies have reported induction of
different NKG2D ligands combined with varying degrees of induction when treated with
HDAC inhibitors [179]. Armeanu et al reported that sodium valproate increases
transcription of MICA/B without affecting ULBPs in hepatoma cells [107]. Diermayr et
al, showed the upregulation of ULBP1 and MICA/B on primary AML cells [180] while
Poggi et al reported the induction of MICA, ULBP2 and ULBP3 on primary AML cells
by sodium valproate [181]. Lopez-Soto et al reported trichostatin A induces ULBPs but
not MICs in epithelial cancer cells. This heterogeneity suggests that diverse molecular
mechanisms are involved in the HDACi effect on the expression of different NKG2D
ligands. Similarly, our results show that HDACi sodium valproate increases MICA

55

mRNA and surface protein with different reaction patterns in the investigated group 2
cell lines.
To investigate other mechanisms that might be responsible for the absence of
surface MICA in the NK resistant leukemia and lymphoma group 2 cell lines, proteolytic
shedding of MICA was explored [86]. Remarkably, under our experimental conditions,
soluble MICA was not detected in the cell culture supernatants suggesting that an
alternate mechanism was responsible for the absence of surface MICA. Intracellular
sequestration of MICA was thus examined. By immunofluorescence microscopy,
intracellular MICA was observed in the group 2 cells but in comparison to the group 1
cell line K562, the levels were considerably lower. In the group 1 cells, both surface and
intracellular MICA was observed while in the group 2 cells it was only seen
intracellularly. The low level of MICA protein was in accordance with the low levels of
mRNA seen in these group 2 cell lines. Next, investigation of the subcellular localization
of MICA by colocalisation markers and confocal microscopy demonstrated substantial
co-localization of MICA with the ER marker calnexin in the group 2 cells and also an
AML patient that lacked surface MICA. We could not detect co-localisation of MICA
with markers for the golgi complex, endosomes or lysosomes. Intracellular retention of
NKG2D ligands in the ER and cis-Golgi has been reported previously in the context of
human CMV infection of fibroblasts [103, 105, 182, 183] but similar phenomenon is not
well established in tumor cells. Our studies demonstrate intracellular sequestration of
MICA in leukemia and lymphoma cells similar to observations made previously in
melanoma [83].
Retention of MICA in the ER could be due to association to chaperones, presence
of ER retention or retrieval sequences such as KDEL or KEDL, post translational
modifications induced by ER quality control mechanisms such as unfolded protein
response and ER associated degradation [184-188]. In fact, it was recently reported that
tumor cell-associated carcinoembryonic antigen (CEA)-related cell adhesion molecule 1
(CEACAM1) causes intracellular retention of MICA/B in human tumor cells [189]. Also,
MICA associates with specific chaperones such as ERp5 that cause cleavage of this
ligand from cell surface of tumor cells [92]. Further studies are warranted to determine
whether an association with these proteins is responsible for absence of surface MICA in
the group 2 cells.
Aberrations in the proteasome system have been associated with a number of
diseases including cancer [190]. Proteasome inhibitors such as bortezomib, have been
licensed for therapy of multiple myeloma and are currently in trails to assess its efficacy
for treatment of other malignancies [191]. Hence, to rescue the intracellularly retained
MICA in our group 2 cell lines, proteasome inhibitor bortezomib was applied to the
tumor cells. An increase in intracellular MICA was observed not only in group 2 cells but
also group 1 cancer cells post treatment with Bortezomib. This suggested that
proteasomal degradation of MICA was a normal physiological process and inhibiting this
by bortezomib may be a simple therapeutic strategy to increase MICA protein. The
increase in intracellular MICA protein resulted in augmented expression of MICA on the
surface of cancer cells. Subsequently, we determined the functional significance of the
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enhanced MICA surface expression on the group 2 cancer cells. An increased NK
susceptibility was observed and the role of the NKG2D pathway was confirmed by antiNKG2D blocking antibody which resulted in a significant abrogation of NK lysis of the
treated cells.
Various groups have published conflicting data on induction of NKG2D ligand
mRNA by bortezomib. Butler et al reported that bortezomib up-regulated ULBP1 mRNA
but not that of the other ligands [170]. Gomez et al reported an increase in ULBP2
mRNA but not MICA/B [169] while Armeanu et al reported that MICA/B mRNA was
up-regulated in response to Bortezomib [192]. The discrepancy in their findings may be
due to different cell lines used in their studies. In our study, MICA mRNA was not
significantly up-regulated after bortezomib treatment in the group 2 cancer cell lines
(Figure A-3) suggesting that the increase in MICA protein was not due to an increased
transcription of the gene. Furthermore, bortezomib has been previously shown to enhance
NK lysis of primary tumors by downregulating surface expression of the inhibitory MHC
class I molecules in myeloma cells [193]. However in our study, analysis of bortezomib
treated primary leukemic patient blasts showed no significant change in the surface
expression of HLA molecules (Figure A-4). Thus, our preliminary observations argue
against downregulation of MHC class I after bortezomib treatment in agreement with
data by Lundqvist et al [194].
Taken together, our data conclusively show that the absence of surface expression
of MICA on the group 2 cells was due to regulation at transcriptional and post
translational levels. Transcriptional repression resulting in low mRNA levels was the
foremost mechanism for the absence of MICA on the surface. Although marginal levels
of protein were observed in some cell lines, intracellular retention in the ER provided a
secondary escape route. Treatment with clinically relevant modulators like HDACi
sodium valproate and proteasome inhibitor bortezomib were able to increase MICA at the
mRNA and/or protein levels, enhanced its surface expression and overcame NK
resistance in the majority of cancer cell lines.
Various reports suggest that ligands are regulated somewhat differently by stress
pathways and that different cellular stresses selectively trigger upregulation of expression
of different sets of NKG2D ligands. This feature presumably allows the same receptor to
stimulate a response in different contexts because of upregulation of distinct ligands.
Although our study used MICA as a model to investigate the mechanism of NK
resistance in the group 2 cell lines, other NKG2D ligands are also under transcriptional,
post transcriptional or translational regulation and they respond differently to different
cellular stresses. From our observations and others, transcriptional repression of MICB
and ULBP genes was also observed. ULBP2 mRNA and surface expression was
significantly upregulated by HDACi treatment while histone acetylation could only
partially rescue MICB and ULBP1 (Figures A-2, A-5 and A-6). The differential effect of
HDACi on the regulation of NKG2D ligands clearly suggests that additional mechanisms
of downregulation may be involved in the regulation of MICB and ULBP1. In fact, Tang
KF et al showed that DNA methyltransferase inhibitor 5-azacytidine could upregulate
MICB by promoting DNA methylation [195]. Furthermore, results from our study on

57

MICA elucidate the possibility of a similar subcellular retention of other NKG2D ligands
particularly MICB and ULBP1 in cancer cells. Further studies are warranted to test these
hypotheses.
NKG2D Ligand Expression Does Not Necessarily Lead to NK Activation
In contrast to the group 1 and group 2 cells, the group 3 cancer cells had an
intriguing phenotype of NK resistance despite a high NKG2D ligand expression. This
novel phenotype, although seen in only 25% of our cancer cell lines, suggests the
existence of mechanisms that can override NKG2D activation. In an effort to uncover the
NK resistance mechanisms in group 3 cell lines, we determined whether intrinsic features
such as PI-9 expression were responsible. It has been shown in mice and in several
cancers that overexpression of PI-9 directly protects cells from apoptosis through
granzyme B inhibition [155, 196, 197]. However, our data revealed no significant
difference in the levels of PI-9 between the resistant group 3 cell lines and the NK
susceptible group 1 cells, suggesting the role of other factors in conferring NK resistance.
Several studies have demonstrated that the cell surface expression of NKG2D
ligands results in an increased susceptibility of MHC class I expressing tumors to NK
cells, thereby suggesting that NKG2D mediated cytotoxicity can override KIR inhibitory
signaling [26, 27, 34]. However, contrasting studies showed that engagement of
inhibitory receptors was able to efficiently block NKG2D-mediated cytotoxicity [44,
198]. In our studies, group 1 cells with high NKG2D ligand expression and high NK
susceptibility illustrated the former observation where NKG2D-mediated cytotoxicity
was able to overcome inhibitory signaling. However, in the group 3 cells that were NK
resistant despite a high NKG2D ligand expression, blockade of inhibitory MHC class I
molecules resulted in an increased NK susceptibility suggesting that strong inhibitory
signaling through KIR could override NKG2D activation in these cancers. This was in
agreement with the observations of Pende et al [44], but in contrast to their data that was
based solely on redirected killing assays, our results provide direct evidence on how
tumor cells may evade NKG2D-mediated cytotoxicity in the natural setting. We also
show that the increased NK lysis of the group 3 cancer cells after HLA blockade was
driven by the NKG2D pathway since blockade of NKG2D resulted in a marked reduction
in NK lysis. This observation further substantiates the role of the NKG2D pathway in
conferring NK susceptibility to cancer cells. Interestingly, HLA blockade on group 1
cancer cells (high NKG2D ligand expression) did not further increase the NK
susceptibility of these cell lines (Figure A-7).
Taken together, HLA blockade experiments with the group 1 and 3 cell lines
clearly demonstrate the ‘dynamic equilibrium’ concept that regulates NK function.
According to this model, NK cytotoxicity is regulated by a fine balance between
activating and inhibitory signals such that if the balance tips towards inhibition, NK lysis
will be inhibited and vice versa. The NK resistant group 3 cells represent the net balance
tipped towards inhibition. However, when the balance is tipped towards activation by
MHC blockade, they become susceptible to NK killing. In contrast, group 1 cells are
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representative of the net balance tipped towards activation and hence their high NK
susceptibility. Moreover, since the net activation has already exceeded the net inhibition
in these cells, MHC blockade does not further augment their NK sensitivity. Although,
mean NKG2D ligand expression scores for the group1 and 3 cell lines were comparable,
the discrepancies in their NK susceptibility post HLA blockade can be speculated to be
due to differences in the expression of other activating ligands that may provide a
synergistic activating signal to NKG2D activation. These include (but are not limited to)
NCR ligands, ligands for other NK co-receptors and also the NKG2D ligands ULBP 4, 5
and 6 that were not included in our study due to lack of specific antibodies and reagents
[44, 199, 200]. Another possibility for the differences observed between group 3 and
group 1 cell lines may be the strength of the negative signal [201, 202] as unpublished
data from ongoing studies in our lab demonstrates variable strength of inhibition by
different HLA alleles.
Nevertheless, HLA blockade on the group 2 cells (lack NKG2D ligands) showed
no increase in NK lysis of these cells, suggesting that the release of inhibition alone is not
sufficient for NK lysis of tumors [24] (Figure A-8). An example of this situation may be
represented by encounters between human erythrocytes and circulating peripheral blood
NK cells. Although human red blood cells do not express the inhibitory MHC class I, NK
cells do not attack them because erythrocytes lack ligands capable of engaging the
activating NK cell receptors [24]. In our study, when MICA was ectopically expressed in
the group 2 cancer cell lines, they were efficiently lysed by NK cells clearly illustrating
that rather than the mere absence of inhibition, the presence of activation is absolutely
required for NK lysis (Figure 4-5). This phenomenon is also clearly demonstrated by two
MHC class I negative cancer cell lines K562 and Daudi. While both cell lines lack
inhibitory ligands, K562 (group 1) is efficiently lysed by NK cells due to the presence of
NKG2D activation ligands but Daudi (group 2) is NK resistant due to the absence of
activating ligands.
Although NK resistance due to KIR inhibition overriding NKG2D activation was
common among the group 3 cell lines, rhabdomyosarcoma line RD was an exception.
Since the RD cells did not show increased NK lysis post treatment with HLA class I
blockade, its ability to activate NK cells was evidently limited. The inability of RD cells
to degranulate NK cells suggests the incapability of these cells to adhere to NK cells.
Conjugate formation between NK cells and its targets is a prerequisite for NK cell
activation and cytotoxicity [203]. Since strong adhesion to target cells mediated by the
adhesion receptor-ligand pair of LFA-1 and ICAM-1 is required for lysis by NK cells
[204, 205], we determined ICAM-1 levels on all group 3 cell lines and found low surface
expression of ICAM-1 specifically on RD. It can be speculated that the low levels of
ICAM-1 impairs NK:target conjugate formation resulting in NK resistance in this cell
line. However, assays to enumerate formally the effector:target conjugates will be
necessary to confirm this hypothesis. The low levels of ICAM-1 on RD cells may be due
to shedding of this molecule as shown in several cancers [206-208] or micro RNA
mediated repression [209].
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Translational Significance of Our Findings
In the past 15 years many groups have reported the anti-cancer effects of NK cells
in humans [114, 210-212]. Strong evidence of the clinical benefits of NK cells was
provided by Imai K et al in 2000 wherein their prospective study of 3625 healthy adults
in Japan with a median followup of 11 years, showed that individuals who had higher
than baseline NK cytotoxicity of K562 cells were at a significantly lower risk of
developing adult cancers [112]. A number of clinical trials with infusion of allogeneic
NK cells in patients with malignant diseases have shown feasibility with no side effects
[213]. Ruggeri et al [114, 214] and others [158, 215] have shown that allogeneic NK cells
can mediate antileukemic effects against AML. However, in a study by Miller et al, only
5 of the 19 AML patients obtained remission after NK transplantation, [216]. Moreover,
all the renal cancer patients in their study did not show a favorable response [216].
Similarly, another study involving 20 patients with recurrent ovarian or breast cancer
showed that NK infusions were well tolerated but no tumor responses were observed
[124]. Several protocols of clinical-grade NK cell purification and in vitro population
expansion are now validated, and studies have shown that the infusion of allogeneic NK
cells is safe in humans [118, 122, 123] but the efficacy of NK cell based tumor therapies
has not yet been firmly established. Although the results of NK based immunotherapeutic
treatments of cancer are promising in the experimental models, till date their clinical
efficacy in human trials has been modest, presumably due to tumor escape by alteration
of NK cell function and resistance to NK killing [217-221].
Our comprehensive study on hematological malignancies and solid tumors
provides fundamental insights concerning the biological mechanisms responsible for the
modest clinical efficacies of NK cell therapy. Specifically, we determined the prevalence
of NK susceptibility in a wide spectrum of cancer cell lines representing various cancer
types. Our observations of NK resistance in the cancer cell lines was further validated by
leukemia patient samples that exhibited 90% NK resistance. Correlation studies on
NKG2D ligand expression and NK cytotoxicity resulted in the observation of 3
phenotypic clusters suggesting that the level of NKG2D ligand expression usually (but
not always) correlates with NK susceptibility. On applying our cell line findings to
patient samples, we observed the group 2 phenotype to be predominant in pediatric
leukemia. Furthermore, induction of NKG2D ligands by HDACi sodium valproate or
proteasome inhibitor bortezomib was conducted on primary patient blasts from an MLL
patient who exhibited a group 2 phenotype with absence of ligands and NK resistance.
The increase in surface MICA and ULBP2 resulting in an increased NK cell
degranulation and augmented NK sensitivity substantiated our findings from the group 2
cancer cell lines. Also, blockade of the inhibitory HLA-KIR interaction on AML blasts
from a representative group 3 patient demonstrated a significant increase in the NK
sensitivity of the patient blasts thereby confirming our group 3 cell line findings. Role of
the NKG2D pathway in conferring NK susceptibility was established by NKG2D
neutralizing antibodies that abrogated NK lysis of the blasts in both the group 2 and
group 3 type patients. Taken together, results from our patient samples mirror our
clustering model and suggest that NKG2D pathway can be modulated clinically.
However, one caveat of our patient data is the inclusion of leukemia samples only. Based
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on the limited clinical effectiveness observed in adoptive NK therapy of solid tumors till
date [124, 222], we speculate similar results on NK resistance and NKG2D pathway
modulation in primary solid tumor samples as well.
Additionally, our clustering plot can be used as a predictive model to determine
the clinical efficacy of NK transplantation in patients (Figure 5-1). Hypothetically, by
analyzing 2 parameters including NK susceptibility and NKG2D ligand expression, we
can determine the likelihood of patient responses to NK cell therapy by grouping them
into phenotypic clusters. For example, if analysis shows the patient blasts to express high
surface NKG2D ligands and high NK susceptibility indicative of the group 1 phenotype,
such a patient would represent an ideal candidate for NK cell therapy. Alternatively, if
the patient shows a low NKG2D ligand expression and NK resistance indicative of the
group 2 phenotype, NKG2D ligands would need to be induced to make this patient’s cells
susceptible to NK lysis. In order to make NK therapy a success in this patient, the
NKG2D ligands would have to be modulated using agents such as HDACi sodium
valproate and/or proteasome inhibitor bortezomib, thereby transforming this patient to a
group 1 phenotype.
Furthermore, if analysis predicts a patient having the group 3 phenotype, blockade
of KIR inhibitory signaling would be beneficial to improve NK susceptibility. In fact, a
therapeutic KIR blocking antibody is currently in clinical trials for AML and multiple
myeloma [219]. This monoclonal antibody 1-7F9, recognizes KIR2DL1, 2, and 3 and
therefore blocks the inhibition imposed by virtually all MHC class I C alleles, allowing it
to be tested in all patients irrespective of their KIR and HLA genotypes [223]. If this
antibody proves successful in clinical trials, it would benefit our group 3 patients
undergoing NK transplantation. Moreover, KIR inhibitory antibody may also be used in
combination with NKG2D ligand inducers such as sodium valproate for further
augmenting NK responses via the NKG2D pathway in group 2 cancer cells [104].
Our study conclusively shows that the NKG2D pathway can be manipulated to
overcome NK resistance thereby improving the immunotherapeutic potential of NK cell
therapy. Modulating this pathway can prove beneficial when used singly or as part of a
multipronged approach to augment the function of NK cells, including the use of
cytokine [224], 4-1BB ligand [140], chimeric antigen receptors [225] and KIR antibody
[223]. Several groups have conducted in vitro and in vivo studies on immune cells
transduced with NKG2D-CAR [146, 150, 225, 226]. The success of such
immunotherapeutic strategies relies heavily on the presence of NKG2D ligands on the
cancer cells. While group 1 and group 3 type cancer cells would be susceptible to lysis by
these CAR expressing cells, the group 2 cells being ligand negative would be resistant.
However, HDACi and/ bortezomib treatment may be applied prior to adoptive transfer of
the NKG2D-CAR bearing cells to ensure clinical efficacy of such therapeutic strategies
[225]. It has been reported that ex vivo expanded NK cells kill NK resistant
neuroblastoma cell lines through the NCR and DNAM-I pathways [157]. Although
effective tumor lysis was observed in this study, we propose that HDACi mediated
NKG2D ligand induction on neuroblastoma lines may present an alternate and clinically
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Figure 5-1. Model for determining strategies for NK therapy.
Cluster plot demonstrating the possible outcomes of NK therapy based on NKG2D ligand
expression and NK susceptibility.
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expedient pathway to enhance tumor lysis. This may be particularly beneficial in donors
that are represented by an NCR dull phenotype since NKG2D receptor is constitutively
and homogenously expressed. In conclusion, the clinical potential of NK immunotherapy
can be enhanced by modulation of the NKG2D pathway. In accordance to the findings of
this study, research in our lab is currently focused on high throughput screening (HTS)
strategies to identify clinically safe drugs capable of modulating the NKG2D pathway.
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CHAPTER 6.

CONCLUSION

Surgery, chemotherapy and ionizing radiation have been used for decades as
primary treatments for cancers. However, the development of resistance to these
approaches has led to significant incidence of tumor relapse. Immunotherapy for cancer
has thus drawn interest given its non-overlapping toxicity with chemotherapy and
radiation therapy and an apparent lack of long term toxicity. In particular, the clinical
potential of the innate immune cells namely NK cells has been harnessed in the treatment
of cancers because they are very good candidates for immunotherapy. NK cells
demonstrate rapid response (cytotoxic in minutes without prior sensitization, high
potency (tumoricidal rather than tumoristatic), broad specificity (easily differentiate
normal cells from tumor cells but do not require different preparations for different tumor
types), potential for optimal donor selection (lab assays), ease of preparation and
administration, lack of side effects (no GVHD and organ toxicity) and complementarity
to other therapeutic strategies (can be administered alongwith antibodies, cytokines, bone
marrow transplantation or gene therapy) [160]. These exceptional qualities have led to
the use of NK transplantation for treatment of hematological malignancies and solid
tumors. However, observation of modest clinical efficacy underscores the need for a
better understanding of the factors that undermine NK therapy.
In an effort to understand some of the reasons that hinder the beneficial effects of
NK cellular therapies, our study comprehensively analyzed a spectrum of 20 cancer cell
lines representing various different cancer types. Analysis of their NK susceptibility
showed NK resistance to be prevalent. Since NKG2D is a major activating receptor on
NK cells, we characterized the role of this pathway in cancer. Heterogeneity in NKG2D
ligand expression was observed among the cancer cells. Correlation between NKG2D
ligand expression and NK susceptibility led to the observation of group 1 cells (high
NKG2D ligand expression, high NK susceptibility), group 2 cells (low ligand expression,
low NK susceptibility), group 3 cells (high ligand expression, low NK susceptibility)
thereby suggesting that ligand expression does not always correlate with NK
susceptibility. Ectopic expression of MICA overcame NK resistance in the group 2
cancer cells suggesting that absence of surface NKG2D ligands was responsible for NK
resistance. Further investigations of resistance mechanisms in the group 2 cancer cells led
to the observations that they lacked surface expression of NKG2D ligands due to low
mRNA and /or protein levels. Transcriptional repression was primarily responsible for
absence of surface ligands. In cells that expressed some protein, ER retention of NKG2D
ligands (particularly MICA) contributed to an additional NK evasion mechanism.
However, treatment with HDACi sodium valproate or proteasome inhibitor bortezomib
helped circumvent these regulatory mechanisms resulting in increased expression of
NKG2D ligands and NK susceptibility. While the lack of NKG2D activation was
responsible for the NK resistance of the group 2 cancer cells, NK resistance of group 3
cancer cells was due to inhibitory signals overriding NKG2D activation. Blockade of the
inhibitory KIR-HLA interaction significantly augmented NK lysis in these cells.

64

Finally, analysis of fresh leukemia patient samples validated our phenotypic
clusters and cell line findings. Taken together, our study conclusively shows that NKG2D
evasion mechanisms are strongly prevalent in cancer; however the NKG2D pathway is
amenable to therapeutic alteration. By using our clustering plot as a predictive model to
determine the efficacy of NK therapy and by implementing therapeutic strategies to
modulate this pathway, greater clinical benefit will be expected for NKG2D-mediated
NK immunotherapy. Thus, NK transplantation holds considerable promise for future NK
cell therapies in cancer.
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APPENDIX. SUPPLEMENTARY FIGURES FOR CHAPTER 5

A

B

Figure A-1. Histone deacetylase inhibitor sodium valproate upregulates mRNA
and protein levels of other NKG2D ligands in neuroblastoma.
(A) Relative MICB, ULBP1 and ULBP2 mRNA levels in untreated (white) and 5mM
treated NB-1691(black) four days after treatment. (B) Histograms of surface MICB,
ULBP1 and ULBP2 on untreated (black) and sodium valproate treated (red)
neuroblastoma cells. Isotype control was presented as shaded histograms. Data are
representative of 3 experiments.
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A

B

Figure A-2. Histone deacetylase inhibitor sodium valproate significantly
upregulated ULBP2 mRNA and protein expression on group 2 leukemia and
lymphoma cell lines.
(A) Relative ULBP2 mRNA levels in untreated (white) and sodium valproate treated
(black) group 2 cancer cells. (B) Histograms of ULBP2 surface expression on untreated
cells (black line) and sodium valproate treated cells (red line) 48 hours after treatment.
Isotype control was presented as shaded histogram. Data are representative of 3
independent experiments.
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Figure A-3. Bortezomib does not increase MICA mRNA.
Relative MICA mRNA levels in untreated (white) and bortezomib treated (black) group 2
cancer cells.
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Figure A-4. Bortezomib does not downregulate HLA-ABC in patient cells.
Histograms of HLA-ABC surface expression on untreated cells (black line) and
bortezomib treated cells (red line) in the indicated patient samples. Isotype control was
presented as shaded histogram.
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A

B

Figure A-5. Histone deacetylase inhibitor treatment marginally upregulated
MICB mRNA and surface protein in the group 2 leukemia and lymphoma cell lines.
(A) Relative MICB mRNA levels in untreated (white) and sodium valproate treated
(black) group 2 cancer cells. (B) Histograms of MICB surface expression on untreated
cells (black line) and sodium valproate treated cells (red line) 48 hours after treatment.
Isotype control was presented as shaded histogram. Data are representative of 3
independent experiments.
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A

B

Figure A-6. Histone deacetylase inhibitor treatment marginally upregulated
ULBP1 mRNA and surface protein in the group 2 leukemia and lymphoma cell
lines.
(A) Relative ULBP1 mRNA levels in untreated (white) and sodium valproate treated
(black) group 2 cancer cells. (B) Histograms of ULBP1 surface expression on untreated
cells (black line) and sodium valproate treated cells (red line) 48 hours after treatment.
Isotype control was presented as shaded histogram. Data are representative of 3
independent experiments.
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A

B

Figure A-7. HLA inhibition does not further increase NK susceptibility of group 1
cells.
(A) Expression of inhibitory ligands HLA-ABC (black line) on the indicated group 1 cell
lines. Isotype control was presented as shaded histogram. Data are representative of 2
independent experiments. (B) NK susceptibility of group 1 cell lines untreated (blue line),
treated with anti- HLA-ABC blocking antibody (red line), treated with anti-NKG2D
antibody (purple line), treated with anti-HLA blocking antibody+anti-NKG2D blocking
antibody (green line) to NK cells at E:T ratios 5:1, 10:1, 20:1. Data are mean % lysis ±
SEM from 3 independent experiments.
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A

B

Figure A-8. HLA inhibition does not increase NK susceptibility of group 2 cancer
cells.
(A) Expression of inhibitory ligands HLA-ABC (black line) on the indicated group 2 cell
lines. Isotype control was presented as shaded histogram. Data are representative of 2
independent experiments. (B) NK susceptibility of group 2 cell lines untreated (blue line),
treated with anti- HLA-ABC blocking antibody (red line), treated with anti-HLA
blocking antibody+anti-NKG2D blocking antibody (green line) to NK cells at E:T ratios
5:1, 10:1, 20:1. Data are mean % lysis ± SEM from 3 independent experiments.
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